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ABSTRACT 
 
Background: Pouchitis, the main complication after ileal pouch-anal anastomosis, 
occurs in 30 to 59% of the patients undergoing such surgery for UC. The aetiology of 
pouchitis is probably a multifactorial event involving genetic, immune, microbial, and 
toxic mediators. Inflammation in the ileal pouch leads to changes in mucosal morphology, 
with consequent decreased vitamin B12, bile acid, and cholesterol absorption documented. 
This study was undertaken to evaluate possible factors predictive for inflammation 
activity and mucosal morphology, to evaluate long-term metabolic consequences, and, 
because manipulating the intestinal microflora by probiotics may prevent pouchitis, to 
evaluate the effect of Lactobacillus rhamnosus GG supplementation as the primary 
therapy for ileal-pouch inflammation. Finally, to study quality of life at least 5 years after 
ileal pouch-anal anastomosis for ulcerative colitis. 
 
Patients and methods: Subjects eligible for study participation were those (n= 241), 
who had undergone restorative proctocolectomy with an ileal pouch-anal anastomosis 
(IPAA) for ulcerative colitis between 1985 and 1994 at the Department of Surgery at 
Helsinki University Central Hospital. The original study population comprised 128 
study subjects: 107 with ileal pouch-anal anastomosis and 21 ileostomy controls. 
Routine blood tests were run, and vitamin status, bile acid absorption, and bone mineral 
density were determined, and endoscopy was done, with biopsies. A pouchitis disease-
activity index, PDAI, was calculated. Fresh faecal samples and biopsies taken from the 
pouch and afferent limb underwent bacterial culture before and after Lactobacillus 
rhamnosus GG supplementation.  
 
Main results: After a mean 7.5-year follow-up, the cumulative incidence of pouchitis 
was 58%. Risk for development of active inflammation (PDAI ≥ 7) was significantly 
higher in patients with preoperative extraintestinal manifestations (OR 2.7, 95%CI 1.1-
6.4, p=0.03). Patients who had had ankylosing spondylitis (AS) or iritis were especially 
at risk. Positive titres of perinuclear antineutrophil cytoplasmic antibodies (pANCA) 
were associated with inflammation in the proximal ileum; 80% of patients with high 
pANCA levels (>100) had pouchitis. Current smokers tended to have a more benign 
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disease course. In patients with pouchitis, faecal concentrations (log10 CFU/g) of 
anaerobes and aerobes were significantly higher (p= 0.007). Degree of villous atrophy 
and colonic metaplasia were both associated with faecal bacterial flora. All the patients 
with conventional ileostomies showed normal mucosal morphology without inflammation. 
In pouch patients with subtotal or total villous atrophy (32.7%), serum levels of albumin, 
calcium, total cholesterol, triglycerides, and vitamin E were significantly reduced (p < 
0.05). The lowest bile acid and vitamin B12 absorption rates were seen in patients with 
inflammation in the proximal limb. Vitamin D deficiency occurred in 10.6%, and vitamin 
A and B12 deficiency in about 5%. In the lumbar spine, 37% of the pouch subjects with 
subtotal to total villous atrophy had osteopenia (Z score < -1), whereas none of the 
IPAA patients with normal villous structure had reduced bone densities in the spine or 
femoral neck. The highest prevalence of osteopenia (66.7%) was found among those 
patients with inflammation in the proximal limb of the pouch.  
A single-strain probiotic bacterium supplementation Lactobacillus GG, did balance the 
faecal bacterial flora, but, based on clinical or endoscopic response, was ineffective as 
primary therapy. In terms of overall satisfaction, the patient groups were similar, with 
90% of conventional ileostomy and 89% of ileal pouch-anal anastomosis patients 
satisfied. 
 
Conclusions: A strong correlation between AS, iritis, and pouchitis suggests a common 
link in their pathogenesis. Metabolic consequences after IPAA are associated with 
pouchitis, grade of villous atrophy, and extent of inflammation in the remaining ileum. 
Vitamin B12 and D levels should be occasionally checked. Patients with extraintestinal 
manifestations and high pANCA levels should be counselled on their high risk for 
developing chronic pouchitis after surgery and on their potential need for long-term 
antibiotic treatment. Patients with conventional ilestomies preserve better mucosal 
morphology, have excellent metabolic outcome, and a good quality of life. Patients with 
chronic pouchitis will need long-term follow-up. 
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INTRODUCTION 
 
Ileal pouch-anal anastomosis (IPAA) has been the operation of choice following 
proctocolectomy for ulcerative colitis (UC) and familial adenomatous polyposis over 
the past 20 years. The most frequently observed long-term complication of IPAA is 
acute and/or chronic inflammation of the ileal reservoir, called pouchitis. The aetiology 
of pouchitis is unknown: the role of genetic susceptibility, faecal stasis with bacterial 
overgrowth, an altered balance in luminal bacteria, nutritional deficiencies, ischaemic 
complications of surgery, and recurrence of UC have inspired speculation. Its 
association with extra-intestinal manifestations supports the hypothesis that pouchitis 
represents ulcerative colitis in the small bowel. All ileal reservoirs show bacterial 
overgrowth. As a response to an altered intraluminal environment, chronic inflammation 
with villous atrophy and incomplete colonic metaplasia occur.  
There is considerable literature on the technical aspects of surgery, on functional 
outcome, and on pouchitis incidence. Less attention has been paid to the long-term 
metabolic consequences that may occur after changes in mucosal morphology and 
inflammation. This thesis aims to address factors associated with ileal pouch 
inflammation and its long-term consequences and prognosis. 
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REVIEW OF THE LITERATURE  
 
1. Ulcerative colitis 
 
Ulcerative colitis is characterised by recurrent episodes of non-infectious inflammation 
in the mucosal layer of the colon (Edwards and Truelove 1963, 1964). It may present at 
any age, but occurs more often in the second or third decade of life, with another peak 
suggested in the 60s (Calkins and Mendeloff 1986). Men and women are equally 
affected. Annual incidence is around 7 cases per 100 000 population (Probert et al. 
1992). The inflammation process almost invariably involves the rectum and may extend 
into the proximal portions of the colon. Confluent inflammation and shallow ulceration 
extend proximal from the anal margin. Virtually all patients with UC have rectal 
bleeding or bloody diarrhoea. Other typical symptoms are urgency, tenesmus, lower 
abdominal cramps, and pain with defecation. In adults at presentation about 55% have 
proctitis, 30% left-sided colitis (the proximal limit being below the splenic flexure), 
15% extensive colitis (involving the transverse colon) or pan colitis. Of patients with 
proctitis, proximal extension occurs in less than 30% (Meucci et. al. 2000). Ulcerative 
colitis is associated with periods of flare-up when the disease becomes more active, and 
periods of remission or inactivity. A large Danish study has examined a total of 1161 
patients with UC for 25 years after diagnosis (Langholz et al. 1994). In that study, 
distribution of disease activity was remarkably constant each year, with approximately 
50% of patients in clinical remission. The cumulative probability of relapse was 90% 
after 25 years of follow-up. The course of the disease changed between remission and 
relapse without significant predictors (age, sex, extraintestinal manifestations, and initial 
localisation), except for disease activity in the initial 2 years after diagnosis. In the 
subsequent 3 to 8 years after diagnosis, 25% of the patients were in remission; 18% had 
activity every year; 57% had intermittent relapses. Activity in the first 2 years after 
diagnosis significantly correlated with an increased probability of disease activity in the 
next 5 years (p=0.00001). 
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1.1. Diagnosis of ulcerative colitis  
 
Colonoscopy is the initial procedure of choice for most patients with suspected IBD. 
Colonoscopy with ileoscopy and biopsy can usually differentiate among ulcerative 
colitis, Crohn´s disease, and other disorders that mimic IBD.  
Endoscopy in UC typically reveals the following findings: erythema, loss of the 
vascular pattern, granularity of the mucosa, friability, oedema, and ulcers. Colonic 
biopsy can serve to confirm diagnosis. The biopsy characteristically reveals distortion of 
crypts, acute and chronic diffuse inflammatory infiltrates, goblet cell depletion, crypt 
abscesses and lymphoid aggregates (Jewell 1998). 
 
1.1.1. Differential diagnosis 
 
It is particularly important at initial presentation to rule out an infectious disease caused 
by Salmonella, Shigella, Campylobacter, Aeromonas, or Escherichia coli 0157:H7. 
Earlier antibiotic therapy may cause Clostridium difficile colitis. Most difficult may be 
to decide whether the diagnosis is ulcerative colitis or Crohn´s disease. The clinical 
manifestations of Crohn´s disease are much more variable than those of UC because of 
transmural involvement and the variability in extent of disease. Three major endoscopic 
findings specific for the diagnosis of Crohn´s disease may help to distinguish it from 
UC: aphthous ulcers, cobblestoning, and discontinuous lesions (Pera et al. 1987). 
Several years may pass after presentation before clinical evolution permits any firm 
decision. In Crohn´s disease, histologic specimens may show focal inflammation, 
submucosal involvement, granulomas, goblet-cell preservation, transmural 
inflammation, and fissuring. 
Otherwise, the differential diagnosis includes anal fissure, collagenous colitis, 
pseudomembranous colitis, ischaemic colitis, diverticulitis, and colonic tumours (Jewell 
1998). 
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1.2. Pathogenesis 
 
1.2.1. Environmental factors 
 
Data from patients and work in animals regarding intestinal inflammation suggest that 
UC results from environmental factors triggering a breakdown in the regulatory 
constraints on mucosal immune responses to enteric bacteria in genetically susceptible 
individuals (Fiocchi 1998, Sartor 2000). The low rates of concordance in monozygotic 
twin pairs with UC (6-14%) compared with rates for with Crohn`s disease (44-50%) are 
the strongest evidence that environmental factors are more important than genetic 
factors in UC pathogenesis (Orholm et al. 2000, Tysk et al. 1988). 
 
1.2.2. Smoking 
 
Ulcerative colitis affects predominantly non-smokers and ex-smokers (Calkins 1989). 
This protective effect against ulcerative colitis and detrimental effect on Crohn`s disease 
remains the most puzzling, but also the most consistent effect (Thomas 2000). Cessation 
of smoking increases the risk for developing UC above that of never-smokers. This 
increased risk persists during the 2 to 3 years following smoking cessation (Motley et 
al. 1987). Nicotine is probably the main active ingredient in this association, but the 
mechanisms remain unknown. Cigarette smoking has effects on cellular (Miller et al. 
1982) and humoral immunity (Srivastava et al. 1991), and raises colonic mucus 
production (Cope et al. 1986). Both smoking and nicotine reduce colonic motility 
(Coulie et al. 2001). Although smoking seems to have no effect on intestinal 
permeability, in UC, colonic mucosal concentrations of the proinflammatory cytokines 
interleukin-1β and interleukin-8 are significantly lower in smokers than non-smokers 
(Sher et al. 1999). In-vivo studies have shown that nicotine also has an inhibitory effect 
on T-helper-2 cell (Th-2) function, which predominates in UC, but has no effect on Th-
1 cells (Madretsma et al. 1996). 
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1.2.3. Diet 
 
Dietary factors have been considered a possible risk factor for UC. In some studies, IBD 
patients have been less likely to be breast-fed than controls (Bergstrand et al. 1983, 
Corrao et al. 1998). Glassman et al. (1990) reported that the frequency of symptoms 
compatible with cow´s milk protein sensitivity during infancy was greater in UC 
(20.9%) than in a control population (2.8%). 
Geerling et al. (2000) reported that high intake of mono- and polyunsaturated fat and 
vitamin B6 may enhance the risk for developing UC. Reif et al. (1997) reported that the 
composition of the preillness diet was related to subsequent development of UC. 
Sucrose and fat consumption were associated with increased risk for UC, but intakes of 
fructose, fluid, magnesium, vitamin C, and fibre from fruit were associated with reduced 
risk. 
Although many foods and food components have been suggested to play a role in 
causing IBD, results are equivocal. However, evidence increases that fermentable 
dietary fibres and prebiotics can modulate various properties of the immune system, 
including those of the gut-associated lymphoid tissues (GALT). Changes in intestinal 
microflora that occur with consumption of prebiotic fibres may potentially mediate 
immune changes via: direct contact of lactic acid bacteria or bacterial products with 
immune cells in the intestine, production of short-chain fatty acids from fibre 
fermentation, or changes in mucin production (Schley and Field 2002). 
 
1.2.4. Role of intestinal flora in mucosal inflammation 
 
The colon has the highest bacterial concentrations in the gastrointestinal tract. More 
than 75% of the wet weight of faecal output is composed of bacterial cells. Each gram 
of faeces is thought to contain 1x1012 microbes, of an estimated 50 genera, belonging to 
over 400 separate species (Savage 1977, Conway 1995). The development of 
“spontaneous” colitis in rats and mice appears to require the presence of luminal flora; 
colitis does not occur in any of several mutant strains when they are maintained in a 
germ-free environment, but develops rapidly when such mice are colonised by 
commensal bacteria (Rath et al. 2001). This suggests that the luminal flora is a requisite 
and perhaps central factor in the pathogenesis of UC. Some commensal organisms can 
  
                                                                                        17                                                                         
 
 
become pathogenic in appropriate circumstances, and the magnitude of this balancing 
act is illustrated by the similarity between proteins of the harmless commensal 
Escherichia coli and its pathogenic derivatives. Burke and Axon (1988) showed distinct 
adherent strains of E. coli in the colonic mucosa of patients with UC, but this has not 
been confirmed by others (Walmsley 1998).  
Colonic mucus and mucosal barrier abnormalities occur in UC patients (Podolsky and 
Isselbacher 1984, Rhodes 1989), as well as an increased number of surface-adherent and 
intra-cellular bacteria in the colonic epithelium with inflammatory bowel disease (IBD) 
(Schultsz et al. 1999, Swidsinski et al. 2002). 
The high prevalence (about 70%) of pANCA in UC (Saxon et al. 1990) and its even 
higher prevalence in patients with primary sclerosing cholangitis (Duerr et al.1991), and 
in refractory left-sided UC are the most reproducible data supporting non-epithelial 
autoimmunity. However, evidence that pANCA is a marker of genetic susceptibility to 
UC has been less convincing (Papo et al. 1996). Rather, it seems to be a marker of 
underlying immune dysregulation. Recent studies have revealed that expression of this 
marker antibody reflects an immune response to the antigen products of enteric bacteria 
(Seibold et al. 1998, Cohavy et al. 2000). Seibold et al. (1998) demonstrated that 
pANCA cross-reacts with mouse caecal bacterial antigen. In addition, Cohavy et al. 
(2000) discovered that pANCA cross-reacts with Bacteroides caccae and E. coli 
commensal bacterial proteins, implicating colonic bacterial proteins as targets of the 
genetically-determined host immune response in UC that generates pANCA. 
 
1.2.5. Role of the immune system 
 
The intestine contains gut-associated lymphoid tissue (GALT) which protects it from 
stimulation by the numerous antigens in the intestinal lumen. When the immunological 
homeostasis of the GALT is destroyed by exaggerated antigens, or dysregulation of 
GALT is induced by unknown agents, inflammation of the intestine may occur. 
Substantial progress has been made in characterising immune-cell populations and 
inflammatory mediators in patients with inflammatory bowel disease and murine 
models (Fiocchi 1998). Reasonable consensus exists that the mucosa of patients with 
established Crohn´s disease is dominated by CD4+ lymphocytes with a type 1 helper-T-
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cell (Th1) phenotype. The mucosa in patients with UC may be dominated by CD4+ 
lymphocytes with an atypical type helper-T-cell (Th2) phenotype. 
Cytokines play a central role in modulation of the intestinal immune system. They are 
produced by lymphocytes (especially T-cells of the Th1 and Th2 phenotypes), 
monocytes, intestinal macrophages, granulocytes, epithelial cells, endothelial cells, and 
fibroblasts (Aggarwal and Puri. 1994). They have proinflammatory functions 
interleukin-1, IL-1; tumor necrosis factor, TNF; IL-6, IL-8, IL-12 or antiinflammatory 
functions (interleukin-1-receptor antagonist, IL-1ra; IL-4, IL-10, IL-11; transforming 
growth factorβ, TGF β (Sartor 1994, Elson 1995). In IBD, mucosal and systemic 
concentrations of many pro- and antiinflammatory cytokines are elevated. Mucosal 
proinflammatory cytokine production correlates with endoscopic activity of UC 
(Ishiguro et al. 1999). An imbalance occurs in the IL-1/IL-1ra ratio between 
proinflammatory and antiinflammatory cytokines in the inflamed mucosa of patients 
with Crohn´s disease, UC, diverticulitis, and infectious colitis (Casini-Raggi et al. 
1995). Furthermore, inhibition of proinflammatory cytokines and the supplementations 
with antiinflammatory cytokines reduced inflammation in animal models, such as the 
dextran sulfate colitis model (Sivakumar et al. 2002), the trinitrobenzene acid model 
(Kanai et al. 2001), or the genetically engineered model of IL-10 knockout mice 
(Rachmilewitz et al. 2002). 
 
1.2.6. Appendectomy  
 
Appendectomy before onset of UC may show a protective effect against UC (Rutgeers 
et al. 1994, Russel et al. 1997, Reif et al. 2001). Appendectomised patients seem to 
have more benign disease course and reduced risk for colectomy (Naganuma et al. 
2001). A large nationwide study from Sweden showed that such a protective and 
beneficial effect was limited to appendectomies performed for an inflammatory 
condition and before the age of 20 years (Andersson et al. 2001). Appendectomy after 
onset of UC does not seem to alter the subsequent course of the disease (Jarnerot et al. 
2001). The importance of an early appendectomy has been shown also by animal 
models (Mizoguchi et al. 1996).  
 
  
                                                                                        19                                                                         
 
 
1.2.7. Genetic factors 
 
A ten-fold increased risk for UC appears among first-degree relatives of patients with 
UC (Orholm et al. 1991). Lifetime risk for UC is higher in Jewish than non-Jewish 
families (Yang et al. 1993). Within the major histocompatibility complex (MHC), the 
human leucocyte antigen HLA genes were the first analysed. An early investigation in a 
randomly selected European population found in UC patients a significantly higher 
frequency of HLA-A11 and HLA-A7 (Asquith et al. 1974). In Japanese and Jewish 
patients, HLA DRB1*1502 is associated with susceptibility to UC and appears more 
often in patients requiring higher doses of steroids (Futami et al. 1995, Toyoda et al. 
1993). Studies in other ethnic groups first revealed conflicting results. More recently, 
however, HLADRB1*0103 and DRB1*12, associated with UC in white populations 
(Satsangi et al. 1996a, Duerr and Neigut 1995, Roussomoustakaki et al. 1997), have 
been suggested to predict disease extent and severity. Genome-wide scanning studies 
have shown linkage between UC and regions of chromosomes 3, 7, and 12 (Satsangi et 
al. 1996b). 
Interleukin (IL)-1α and IL-β are major proinflammatory cytokines involved early in the 
inflammatory cascade. The interleukin 1 receptor antagonist (IL-1 ra), the natural 
inhibitor of these IL-1 agonists, acts by competitively binding to IL-1 receptors without 
eliciting signal transduction (Arend 1993). All three proteins are coded by genes in the 
IL-1 gene cluster on the long arm of chromosome 2 (Nicklin et al. 1994). Biological 
observations both in animal models of colitis (Ferretti et al. 1994) and in patients with 
IBD suggest that an imbalance in the biologically important IL-1 ra/IL-1 ratio may 
contribute in UC to the chronic inflammatory response (Casini-Raggi et al. 1995). Such 
evidence suggests that the IL-1 gene locus is an appropriate candidate region for 
determinants of both genetic susceptibility and disease phenotype in UC. 
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1.3. Extraintestinal manifestations and complications 
 
1.3.1. Extraintestinal manifestations 
 
Mechanisms responsible for the extraintestinal manifestations of IBD, the most 
common of which are listed in Table 1, are not clearly understood. The majority of 
extraintestinal manifestations are related to immunologic mechanisms and associated 
with the production of various cytokines (Sartor 1994). A process central to the 
occurrence of extraintestinal manifestations is the development of self-reactive B cells, 
which are triggered to produce IgG autoantibodies directed against cell surface targets 
(Naparstek and Plotz 1993). Shared antigens probably play a significant role in the 
pathogenesis of extraintestinal manifestations. A colon epithelial protein (p40) has been 
identified with unique crossreactivity to the biliary tract, skin, eyes, and joints (Das et 
al. 1993). The monoclonal antibody developed against p40 binds specifically to colon 
epithelial cells. The corresponding epitope reactive to this antibody has been detected in 
biliary epithelium, in keratinocytes, in the nonpigmented ciliary epithelium of the eyes, 
and in chondrocytes (Das et al. 1990, Bhagat et al. 1994). This pattern of selective 
reactivity matches well the established extracolonic complications in UC. 
 
Table 1. Extraintestinal manifestations of ulcerative colitis 
 
 Prevalence 
% 
Reference 
Related to activity of colitis 
  Peripheral arthritis 
  Erythema nodosum 
  Iritis, uveitis 
  Thromboembolism 
 
10-12 
0.9-4 
0.5-3.2 
1.3 
 
de Vlam et al. 2000, Palm et al. 2001 
Orchard et al. 1998, Greenstein et al. 1976 
Bernstein et al. 2001, Goudet et al. 2001 
Talbot et al. 1986 
Unrelated to activity of colitis 
  Sclerosing cholangitis 
  Ankylosing spondylitis,    
  Sacroileitis 
  Pyoderma gangrenosum 
 
2–7 
1.6-7 
4-18 
1-2 
 
Olsson et al. 1991, Raj et al. 1999 
Monsen et al. 1990, Bernstein et al. 2001,  
Dekker-Sayes et al. 1978, de Vlam et al. 2000 
McCallum et al. 1968, Mir-Madjlessi et al. 
1985 
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1.3.2. Metabolic bone disease 
 
Osteopenia or osteoporosis is a common finding in IBD (Bjarnason et al. 1997). 
Decreased bone mineral density (BMD) has been reported in 31 to 59% of patients with 
IBD (Abitbol et al. 1995, Andreassen et al. 1997, Pollak et al. 1998). Osteopenia may 
be more common in patients with Crohn´s disease than in those with UC (Ardizzone et 
al. 2000). The mechanism of bone loss in IBD is likely to be multifactorial. Various 
factors such as extent of small bowel involvement, ileal resection, malnutrition, calcium 
malabsorption, vitamin-D deficiency, prolonged use of corticosteroids, and reduced 
physical activity may disturb bone metabolism (Tromm et al. 1993, Scharla et al. 1994, 
Abitbol et al. 1995, Silvennoinen et al. 1995). Strong evidence exists that high 
inflammatory activity itself, with circulating cytokines, induces bone loss, with 
suppression of bone formation (Lin et al. 1996, Bjarnason et al. 1997). 
 
1.4. Medical therapy for ulcerative colitis 
 
Standard medical therapy for UC is predominantly based on the use of oral or topical 
preparations of aminosalicylates and corticosteroids. Aminosalicylates are used to treat 
mild-to-moderate disease and are the major drugs for maintaining remission. 
Corticosteroids and immunosuppressants are used for active disease or refractory 
disease. 
 
 1.4.1. 5-aminosalicylates (5-ASA) 
 
Sulphasalazine is the oldest (since 1942) and the least expensive of the 
aminosalicylates, and has been recognised for many years to be useful for preventing 
flare-ups of UC; 5-aminosalisylates (5-ASA), like mesalazine, the active component of 
sulpasalazine, has the therapeutic benefits without the majority of the related side-
effects. The response rate to 5-ASA administered orally is 54 to 88% (Hanauer 2000). 
Topical mesalazine has performed better than oral mesalazine and topical 
corticosteroids for patients with active distal colitis (Sutherland et al. 2000), whereas 
combination oral and topical 5-aminosalicylates has been more effective than either 
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drug alone for induction (Safdi et al. 1997) and maintenance (d´Albasio et al. 1997) 
treatment of mild-to-moderate distal disease. All patients should receive the maximum 
tolerated dosage of aminosalicylates, including combination therapy if distal disease is 
present, for at least 4 to 6 weeks before topical or oral corticosteroids are considered. 
 
1.4.2. Corticosteroids  
 
Corticosteroids are the mainstay of treatment of severe disease. These may be given 
orally or intravenously, usually in a daily dose of 60 to 80 mg methylprednisolone 
intravenously, or 40 to 60 mg prednisolone orally. They have a number of potential side 
effects, which include weight gain and other effects of fluid retention, osteoporosis, 
increased blood sugar and blood pressure, higher risk of infection, acne, and menstrual 
problems. After remission is induced, the corticosteroid dose should be tapered over 8 
weeks until the drug is discontinued (Hanauer 2000). 
 
1.4.3. Immunosuppressants 
 
Azathioprinre and 6-mercaptopurine can prevent relapse, even when used alone, and in 
some studies are effective for maintaining remissions in UC that have lasted at least 2 
years (Hawthorne et al. 1992). The response rate to these immunosuppressants is 50-
64% (Hanauer 2000). 
Cyclosporin, given intravenously (4 mg/kg) (Lichtiger et al. 1994) or orally (4-9 mg/kg) 
has proven successful in inducing remission in 60 to 80% of patients (Carbonnel et al. 
1996) in acute relapses of UC. Long-term follow-up studies of patients treated with 
cyclosporin have shown that 53 to 62% avoid colectomy during a 3- to 5-year follow-up 
(Stack et al. 1998, Cohen et al. 1999). Addition of azathioprine or 6-mercaptopurine to 
treatment regimens is recommended for all patients who respond to cyclosporin (Cohen 
et al. 1999).  
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2. Surgery for ulcerative colitis 
 
Although drugs and medical therapy are central in the treatment of UC, surgery has an 
important role in relieving symptoms, addressing serious complications, and improving 
quality of life.  
Indications for surgery in ulcerative colitis are 
• failed medical treatment  
 chronic disease, recurrent acute exacerbations, steroid dependence  
 severe symptoms in an otherwise systemically well patient  
• fulminant colitis, perforation, or toxic megacolon 
• severe dysplasia or carcinoma of the colonic epithelium 
 
 
 
2.1. Choice of operation 
 
Four operations are available for patients undergoing surgery. 
 
2.1.1. Conventional proctocolectomy and ileostomy 
 
Proctocolectomy with construction of a conventional ileostomy has remained the 
favourite for curative treatment of UC over the years. The evolution of ileostomy 
technique from spontaneus maturing stoma to eversion stoma according to Brooke 
(1952), with the advent of enterostomal care (stomatherapy with modern appliances) 
allows a full, active life for most patients today. Admittedly, some patients do have 
daily problems, and for others the mere change of body image leads to serious 
psychosocial consequences (Awad et al.1993). 
Panproctocolectomy is a rationale procedure. It removes all diseased mucosa and is in 
this respect curative. The technique is well established; it can be performed with low 
mortality and morbidity, and convalescense is rapid. However, complications related to 
the ileostomy and the perineal wound contribute to considerable postoperative 
morbidity (Leong et al. 1994, Valkamo 1981).  
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The most common complications of an ileostomy are presented in Table 2. 
 
Table 2. Long-term complications of conventional ileostomy (Valkamo 1981) 
Complication            Incidence % 
Retraction                12.8 
Prolapse                   
Stenosis                    
2.4 
9.6 
Peristomal abscess   
Fistula                      
Peristomal hernia     
0.8 
5.6 
8.8 
 
The cumulative risk for needing an ileostomy revision is about 40% over a 10-year 
period (Carlstedt et al. 1987). 
For a patient with an ileostomy, an acute gastroenteritis can lead to rapid dehydration 
and a life-threatening situation. Intravenous fluids and electrolyte replacement are 
needed until the illness resolves. Patients must be warned of this danger, especially if 
travelling abroad. 
 
2.1.2. Continent ileostomy: Kock pouch 
 
Nils Kock reasoned that a pouch and nipple valve constructed of terminal ileum could 
store ileal contents internally until emptied voluntarily by passage of a large, soft 
catheter several times daily, obviating an external appliance. During the 1970s and early 
1980s, the Kock continent ileostomy was the primary option for patients requiring 
surgery for UC but who wished to avoid a permanent conventional ileostomy. Late 
complications were usually related to the nipple valve. The most common reason for 
pouch excision was partial or total nipple-valve sliding (Lepistö and Järvinen 2003). An 
internal fistula sometimes develops through the base of the nipple valve and results in 
leakage of intestinal contents (Kock et al. 1986). Another distressing long-term 
complication has been pouchitis, which occurs in from 10% to 45% of patients (Church 
et al. 1987, Zuccaro et al. 1989). 
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2.1.3. Colectomy with ileorectal anastomosis 
 
Colectomy with ileorectal anastomosis should be considered in patients who have a 
rectum of adequate distesibility that is not particularly inflamed. The operation is 
simple, with rapid recovery. However, the disease persists in the rectum. There is a 
reported failure rate of 10 to 50% due to poor function resulting from persisting 
inflammation or neoplastic transformation (Nicholls 2002). 
 
2.1.4. Ileal pouch-anal anastomosis (IPAA) 
 
The introduction of restorative proctocolectomy for patients with UC in the late 1970s 
(Park and Nicholls 1978) was greeted with enthusiasm because patients no longer had to 
accept a permanent ileostomy. Thus, panproctocolectomy with ileal pouch-anal 
anastomosis has become the treatment of choice for the majority of patients requiring 
surgery for ulcerative colitis. It permits removal of all pathological large bowel mucosa 
while preserving intestinal continuity and continence.  
 The anal sphincter is preserved and an ileoanal anastomosis is constructed after the 
creation of an ileal reservoir to act as a neo-rectum. The operation may be carried out as 
a one- or two-stage procedure. There is evidence that long-term outcome is improved if 
a temporary ileostomy is constructed (Nicholls 2002). Contraindications include 
Crohn´s disease, acute severe colitis, low rectal carcinoma, disseminated carcinoma, and 
poor anal sphincter. Relative contraindications include the presence of an anal lesion 
and sclerosing cholangitis (Penna et al. 1996). There is now evidence that fertility is 
reduced by about half in female patients undergoing the operation, and all females of 
child-bearing age must be fully counselled (Olsen et al. 1999). 
Creation of a pouch results in stasis, creating a new ileal environment. Because of either 
stasis or the density of the bacterial population, the mucosa of the pouch develops villous 
atrophy and crypt elongation and a raised crypt-cell proliferation rate with an infiltration of 
lymphocytes and eosinophils (Shepherd 1987, de Silva et al. 1991a).  
After ileal pouch-anal anastomoses, the villous morphology alters as early as in 5 days 
(Kühbacher et al. 1998). Mucin histochemical analysis reveals development of a colonlike 
mucosal morphology. A switch from sialomucin (produced by the small bowel) to 
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sulphomucin (produced by the large bowel) ocurs in about 50% of patients (Moskowitz et 
al. 1986, Shepherd et al. 1987). The histological changes appear to be more prominent in 
the distal pouch than in the proximal mucosa (Setti Carraro et al. 1998). These changes in 
epithelial cell morphology were initially identified as colonic metaplasia. However, they 
do not affect the pouch uniformly. Both the adaptive and the inflammatory changes are 
focal in response to static faecal residue. Other studies, however, suggest that exposure to 
the faecal stream rather than the stasis appears to be the most important stimulus for 
observed changes (de Silva et al. 1991a, de Silva et al. 1991b). The mechanisms 
underlying colonic metaplasia are likely to be influenced by an interactions between 
bacteria, short-chain fatty acids (SCFA), and bile acids. Although histological changes 
resemble those of metaplasia, complete transformation of the epithelium does not occur. 
Morphological changes in the pouch epithelium may be a prerequisite for the development 
of pouchitis (Shepherd et al. 1993). 
 
 
3. Long-term prognosis after ileal pouch-anal anastomosis 
 
Despite its being a technically challenging procedure, post-operative mortality in IPAA 
approaches zero (Meagher et al. 1998). However, once the pouch is functioning, more 
than 50% of patients will suffer some of a number of problems (Tables 3 and 4). 
 
Table 3. Main post-operative complications of ileal pouch-anal anastomosis after UC 
Complication % Reference 
Pouchitis 30-59 Hurst et al.1996, Meagher et al.1998, Simchuk et al. 
2000, Tiainen and Matikainen 2000, Heuschen et al. 
2001a 
Pelvic sepsis  3-5 Meagher et al. 1998, Johnson et al. 2001 
Stricture 4-11 Dayton et al. 2002, Prudhomme et al. 2003 
Fistulae 1.6-5 Dayton et al. 2002, Breen et al. 1998 
Dysplasia/cancer < 0.5 Thompson-Fawcett et al. 2001, Heuschen et al. 2001b 
Pouch failure 0.3-5.3 Keränen et al. 1997, Dayton et al. 2002, Fazio et al.1995, 
Lepistö et al. 2002 
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Table 4. Long-term functional outcome of ileal pouch-anal anastomosis after surgery  
for UC 
 
  Reference 
Number of stools/ 24h 5-7 Keränen et al. 1997, Meagher et al. 1998, 
Johnson et al. 2001 
Need for night evacuation 40-80% Romanos et al. 1997, Keränen et al. 1997 
Urgency 6-10% Romanos et al. 1997 
Incontinence 
      Occasional 
      Frequent 
 
39% 
7% 
 
Meagher et al. 1998, Tiainen and Matikainen 
2000 
Use of retarding drugs 29-75% Keränen et al. 1997, Romanos et al. 1997, 
Johnson et al. 2001 
Protective pads 17-30% Meagher et al. 1998, Johnson et al. 2001 
Perianal soreness 30-48% Meagher et al. 1998, Johnson et al. 2001 
 
 
3.1. Pouchitis 
 
3.1.1. Incidence 
 
The most frequent long-term complication after ileal pouch-anal anastomosis for UC is 
pouchitis, a non-specific inflammation of the ileal reservoir (Sandborn 1994, Kühbacher 
et al. 1998), but a standardised definition of and diagnostic procedures for pouchitis are 
lacking. Reported rates of incidence of pouchitis in patients operated on for UC range 
between 30 and 59% (Simchuk et al. 2000, Hurst et al. 1996, Meagher et al. 1998, 
Heuschen et al. 2001a). Acute pouchitis has a much higher frequency than chronic 
pouchitis. Penna et al. (1996) reported a cumulative risk for developing pouchitis at one, 
two, five, and ten years after ileal pouch construction of 16, 23, 36, and 46%, 
respectively, for patients with UC. Keränen et al. (1997) found at 11 years a cumulative 
overall risk for pouchitis of 28% and a cumulative risk for 5% for chronic pouchitis. 
Luukkonen et al. (1994) demonstrated in UC patients a cumulative risk of developing 
chronic pouchitis of 5% at 4 years and 7% at 6 years. 
A considerable number of cases of pouchitis have proven to be caused by surgical 
complications (secondary pouchitis)  specific to the ileal reservoir and ileoanal 
anastomosis procedure (pouch-anal fistulas and peripouchal abscesses, outlet 
obstruction) (Scott and Phillips 1989, Fleshman et al. 1988, Fischer et al. 1993, 
Galandiuk et al. 1990, Belliveau et al. 1999, Heuschen et al. 2001a). Differentiation 
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between primary and secondary pouchitis is important because it determines the mode 
of therapy. Secondary pouchitis caused by surgical complications requires surgical 
treatment in nearly all cases (Heuschen et al. 2001a). 
 
3.1.2. Symptoms 
 
Typical predominant symptoms of acute exacerbation of pouchitis are an increase in 
stool frequency with loose to watery stool. Abdominal cramping, bleeding per anus and 
systemic malaise are less common. Exacerbation of extraintestinal manifestations such 
as arthalgia, arthritis, iritis, erythema nodosum, and pyoderma gangrenosum occur 
infrequently (Lohmuller et al. 1990, Goudet et al. 2001).  
Shen et al. found that symptoms, endoscopic findings, and histological abnormalities do 
not correlate with each other, which further shows that symptoms alone do not predict 
the finding of pouch inflammation. In addition, endoscopic and histologic inflammation 
are not always associated with the presence of severe symptoms, as demonstrated by the 
fact that 36% of patients with minimal symptoms had significant endoscopic and 
histologic inflammation. And vice versa, 25% of patients with a high symptom score 
suggestive of pouchitis did not fullfill criteria for the diagnosis of pouchitis (Shen et al. 
2001a). Thus, the diagnosis of pouchitis should always be made on the basis of clinical, 
endoscopic, and histologic features (Moskowitz et al.1986, Madden et al. 1990, de Silva 
et al. 1991b, Sandborn et al. 1994a, Luukkonen et al. 1994, Veress et al. 1995, Shen et 
al. 2001a). 
 
3.1.3. Endoscopic findings and histologic changes 
 
During endoscopy, the presence of mucosal oedema and erythema, granularity, contact 
bleeding, friability, loss of vascular pattern, and ulceration indicate pouchitis, but these 
changes may be patchy (Moskowitz et al. 1986, Di Febo et al. 1990).  
For histological assessment it is important that biopsies are taken from the anterior and 
posterior wall, avoiding suture lines. Attention should be directed toward acute 
(polymorph infiltration, crypt abscesses, ulceration) and chronic inflammation (chronic 
inflammatory cell infiltration, villous atrophy). Other histological findings include low 
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intra-epithelial lymphocyte density and goblet-cell depletion (Shepherd et al. 1987, 
1993, de Silva et al. 1991b). 
 
3.1.4. Scoring the severity of inflammation 
 
 The first disease activity index was developed by Sandborn et al. at the Mayo Clinic in 
Rochester, Minnesota 1994. An overall Pouchitis Disease Activity Index (PDAI) score 
is calculated from three separate 6-point scales for clinical symptoms, endoscopic 
findings, and histologic changes. Patients with a total PDAI score of 7 or higher are 
classified as having pouchitis (Sandborn et al. 1994b) (Table 5).  
The Heidelberg Pouchitis Activity Score (PAS), presented in the year 2001 by 
Heuschen et al. takes into account also chronic inflammatory infiltration when scoring 
the severity of pouchitis (Heuschen at al. 2001a). In that scoring system, grade I 
inflammation (score 4-12) is defined as mild adaptive inflammation, because it is almost 
universal. Grade II inflammation (score 13-24) represents moderate pouchitis. Grade III 
inflammation (score 25-36) is defined as severe pouchitis (Table 6). 
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Table 5. Pouchitis disease activity index (PDAI): maximum 18 points 
 
Criteria  Score 
Clinical Post-operative stool frequency 
   Usual 
   1-2 stools/day more than usual 
   3 or more stools than usual 
Rectal bleeding 
   None or rare 
   Present daily 
Faecal urgency/ abdominal cramps 
   None 
   Occasional 
   Usual 
Fever 
   Absent 
   Present 
 
0 
1 
2 
 
0 
1 
 
0 
1 
2 
 
0 
1 
Endoscopic Oedema 
Granularity 
Friability 
Loss of vascular pattern 
Mucus exudate 
Ulceration 
1 
1 
1 
1 
1 
1 
Histological Polymorph infiltration 
   Mild 
   Moderate + crypt abscess 
   Severe + crypt abscess 
Ulceration 
   <25% 
   >25%, <50% 
   >50% 
 
1 
2 
3 
 
1 
2 
3 
Pouchitis is defined as a total score of >7 
Sandborn et al. Mayo Clinics Proceedings 1994;64:409-415 (b) 
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Table 6. The Heidelberg Pouchitis Activity Score (PAS): maximum 36 points 
CLINIC Score  Score 
 Stool frequency/24 hours 
     < 8 
     8-10 
    11-13 
     >13 
Faecal urgency 
    absent 
    present 
 
0 
2 
4 
6 
 
0 
3 
 Rectal bleeding 
    Absent 
    present 
 
0 
3 
 
 
 
 
             
Max. 12 
ENDOSCOPY    
Oedema 
     absent 
     present 
Friability 
     absent 
     mild 
     severe 
Flattening of mucosal surface 
    absent 
    present  
 
0 
1 
 
0 
1 
2 
 
0 
2 
Granularity 
    absent 
    present 
Erythema 
    absent 
    mild 
    severe 
Ulcerations/Erosions 
    absent 
    mild 
    severe 
 
0 
1 
 
0 
2 
3 
 
0 
2 
3 
Max. 12 
HISTOLOGY    
Acute histologic inflammation 
 
  Polymorphonuclear leukocyte  
  infiltration 
    absent 
    discrete or patchy 
    moderate with (±) crypt     
    abscesses or cryptitis 
    extensive with (±) crypt  
    abscesses or cryptitis 
Ulceration/Erosions 
    absent 
    mild and superficial 
    moderate 
    extensive 
 
 
 
0 
1 
2 
 
3 
 
 
0 
1 
2 
3 
Chronic histologic inflammation 
 
 Mononuclear leukocyte  
  infiltration 
    absent 
    mild and patchy 
    moderate 
    extensive 
 
Villous atrophy 
    absent 
    minimal 
    partial 
    subtotal/total 
 
 
 
 
0 
1 
2 
3 
 
 
0 
1 
2 
3 
Max. 12 
Heuschen et al. Dis Colon Rectum 2001;44:487-499 
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3.2. Pathogenesis of pouchitis  
 
3.2.1. Bacterial overgrowth 
 
In the pathogenesis of pouchitis, a major contributing factor is faecal stasis with 
bacterial overgrowth. Most episodes of pouchitis are single attacks usually responding 
to metronidazole or to antimicrobial combination therapy (Mimura et al. 2002). In ileal 
reservoirs without signs of pouchitis, the microflora closely resembles the flora of the 
large bowel. This mainly due to the large numbers of anaerobes, resulting in a greater 
ratio of anaerobes to aerobes (Luukkonen et al. 1988, Go et al. 1988, Nasmyth et al. 
1989, Santavirta et al. 1991a). The pouches of patients with pouchitis, however, harbour 
increased concentrations of anaerobes (Onderdonk et al. 1992) and aerobes, a reduced 
ratio of anaerobes to aerobes, with reduced counts of Lactobacillus and Bifidobacterium 
(Ruseler-van Emden et al. 1994).  
These increased numbers of bacteria appear responsible for the increased crypt cell 
production rate and villous atrophy observed in the pouch mucosa soon after 
construction of a reservoir (Philipson et al. 1975). Nasmyth et al. (1989) found a 
significant correlation between number of isolated Bacteroides and the grade of villous 
atrophy. The greater the number of Bacteroides the more severe was the villous atrophy. 
 
3.2.2. Recurrence of ulcerative colitis? 
 
Pouchitis occurs almost exclusively in patients who undergo colectomy for ulcerative 
colitis. In a recent study, the cases of pouchitis in familial adenomatous polyposis (FAP) 
patients were all secondary forms (pouch-anal fistula) (Heuschen et al. 2001a).  
Cytokine production in pouchitis resembles that in ulcerative colitis. Relative to 
inflamed pouches or to normal ileal mucosa, mucosal biopsy specimens from inflamed 
pouches have demonstrated an increased CD4:CD 8 ratio, increased expression of T-cell 
activation markers such as CD25, and an increased number of interferon γ-producing 
cells (Stallmach et al. 1998). In addition, studies have demonstrated an increased 
expression of proinflammatory cytokines such as interleukin 1 (IL-1), IL-6, IL-8, and 
tumor necrosis factor α (TNF-α) in ileal reservoirs of patients relative to those in non-
inflamed pouches (Gionchetti et al. 1994, Patel et al. 1995, Ulisse et al. 2001). 
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Neuromediators, including substance P (Keränen et al. 1996, Watanabe et al. 1998), 
may thus be able to modify intestinal inflammatory reactions (Anton and Shanahan 
1998) by direct regulation of immune cells. 
That overproduction of nitric oxide (NO) by inducible NO synthase (iNOS) may 
contribute to the pathophysiology of both UC and pouchitis (Southey et al. 1997) has 
been suggested in animal models (Southey et al. 1997) and in studies of UC and 
pouchitis (Kimura et al. 1998, Rachmilewitz et al. 1998). It has been proposed that NO 
is the main inductor of IL-8 and is associated with an increase in cyclo-oxygenase 2, 
tumor-necrosis factor (TNF) α, and IL-1β expression. Because NO has also been shown 
to be a neurotransmitter in the noradrenergic-noncholinergic inhibitory nerves in the 
human gut, it is therefore regarded as an important contributor to the motility problems 
seen in acute UC. Motility studies have shown NO to act more strongly in the UC colon 
than in the normal colon (Tomita and Tanjoh 1998). Producers of NO are most likely 
macrophages and neutrophils within the colonic or pouch mucosa (Ikeda et al. 1997).  
 
3.2.3. Short-chain fatty acids 
 
Stools of patients with active pouchitis have been reported to contain decreased 
concentrations SCFAs (Sagar et al. 1995, Clausen et al. 1992). In contrast to these 
studies, Sandborn and colleagues (1995) could not demonstrate any decreased faecal 
concentration of short-chain fatty or bile acids. Short–chain fatty acids are an important 
energy source for the colonic epithelium, and their deficiency may cause diversion 
colitis (Harig et al. 1989). Butyrate is a major fuel for the colonic mucosa and may 
inhibit cell proliferation and stimulate cell differentiation (Phillips et al.1995). It has 
been proposed that in the pouch, low pouch concentrations of fermentable saccharides 
reduce the production of short-chain fatty acids by faecal bacteria (Clausen et al. 1992). 
Nasmyth´s group (1989) observed a negative correlation between concentration of 
butyrate in the pouch effluent and severity of villous atrophy of the pouch mucosa. 
Pouchitis may be due to a reduction in substrate availability, leading in turn to low 
SCFA, and it may respond to instillation of SCFA into the pouch by enema, but the 
benefit varies depending on the report (de Silva et al. 1989, Wischmeyer et al. 1993, 
Ambroze et al. 1993). 
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3.2.4. Mucosal ischaemia  
 
Doppler studies have been shown that mucosal blood flow in pelvic reservoirs is 
significantly lower than mucosal bloodflow in conventional ileostomies (Perbeck et al. 
1985). Transient mucosal ischaemia may cause oxygen-derived free radical production 
by xanthine oxidase inhibitor, in patients with acute and chronic pouchitis. Allopurinol 
is a scavenger of oxygen-derived free radicals. To investigate the role of this xanthine 
oxydase inhibitor, Joelsson et al. (2001) conducted a study in 184 patients with ileal 
pouch-anal anastomosis randomized to receive postoperative prophylactic allopurinol 
100 mg twice daily or placebo. The allopurinol failed to reduce risk for a first attack of 
pouchitis.  
Moreover, the same surgery is used to treat patients with familial adenomatous 
polyposis (FAP), in whom the incidence of pouchitis is very low (Kartheuser et al. 
1996), which suggests that ischaemia is not the cause of pouchitis (Mahadevan and 
Sandborn 2003). 
 
3.3. Risk factors for the development of pouchitis 
 
Several independent risk factors for pouchitis have been identified. 
• Previous course of the disease (high relapse rate, chronic refractory disease) 
• Presence of extraintestinal manifestations such as primary sclerosing cholangitis 
• High pANCA (> 100 ELISA units /ml) 
• Cessation of smoking  
• Genetic factors 
 
Episodes of pouchitis are associated with extra-intestinal manifestations characteristic 
of UC. Furthermore, an association exists between such manifestations occurring prior 
to surgery and subsequent development of pouchitis. Patients with primary sclerosing 
cholangitis (PSC) are particularly at risk for pouchitis (Penna et al. 1996, Aitola et al. 
1998). The cumulative risk for pouchitis at 10 years after ileal pouch-anal anastomosis 
has been 45.5% without PSC and 79% for patients with PSC (Penna et al. 1996). 
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Orthotopic liver transplantation in patients with sclerosing cholangitis and ileal pouch 
anal anastomosis does not alter risk for developing pouchitis (Zins et al. 1995). 
The presence of antibodies directed against neutrophil granulocytes and which show a 
characteristic perinuclear binding pattern (pANCA) was initially regarded as a strong 
risk factor and has been advocated to play a primary role in pouchitis pathogenesis. 
Some studies have shown that proctocolectomy leads to a reduction in pANCA titres 
(Esteve et al. 1996, Aitola et al. 1995). However, a recent study by Fleshner et al. 
(2001) reported that high levels of pANCA (>100 ELISA units/ml) before colectomy 
are significantly associated with development of chronic pouchitis after IPAA. The 
cumulative risk for chronic pouchitis in these high-pANCA patients was 56%, 
compared to 22% in medium-level (40-100 EU/ml), 16% in low-level (<40 EU/ml), and 
20% in pANCA-negative patients (p=0.005) (Fleshner et al. 2001). 
Smokers seem to have fewer episodes of pouchitis than do nonsmokers or former 
smokers. Pouchitis occurred in 18 of 72 non-smokers, in 4 of 12 ex-smokers but in only 
one of 17 smokers (Merret et al. 1996). It appears that the effect of smoking on 
pouchitis parallels that seen in UC (Thomas et al. 1998). 
Carter and colleagues (2001) reported that after IPAA for UC, the interleukin 1 
receptor-antagonist gene allele 2 predicts pouchitis. Patients with pouchitis had a higher 
allele-2 carriage rate than did those without pouchitis (72% vs. 45%), and Kaplan-Meier 
survival analysis showed that allele-2 carriers had a significantly higher incidence of 
pouchitis than did noncarriers (log-rank test, 6.5). 
 
3.4. Consequences of colectomy and IPAA 
 
3.4.1. Anaemia 
 
In a recent study by Tiainen and Matikainen (2000) the prevalence of anemia in IPAA 
cases at the time of the study visit was 20.8%. Severe or chronic pouchitis exposed 
patients to anemia, with iron deficiency occurring in 10.4%.  
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3.4.2. Electrolyte imbalance 
 
Changes in water and sodium balance after IPAA are similar to those after conventional 
ileostomy. Santavirta et al. (1991b) studied water and electrolyte balance in 30 patients 
with IPAA, 10 patients with conventional ileostomy, and 9 non-operated patients with 
quiescent ulcerative colitis. Serum chloride in IPAA patients was significantly lower 
than in the other groups. Daily urinary loss of sodium in non-surgical patients was 
significantly higher than in patients with an ileal pouch or conventional ileostomy. 
Daily faecal weight, urinary volume, and urinary excretion of sodium were similar in 
patients with IPAA and ileostomy. Using tritiated water and a bromide dilution 
technique, Christie et al. (1990) showed that in patients with IPAA the body content of 
water and extracellular fluid are normal. 
 
3.4.3. Malabsorption  
 
Resection of the ileum together with bacterial colonisation may lead to villous atrophy 
and thus to loss of absorptive mucosa. These changes may lead to reduced absorption of 
bile acids, lipids, and vitamin B12.  
Increased faecal bile acid excretion after IPAA has been well documented (Hylander et 
al. 1991, Natori et al. 1992). Santavirta et al. (1990) found that IPAA patients with low 
retention of bile acids had more severe villous atrophy than those with high retention. 
However, bile acid malabsorption is seldom severe enough to impair micelle formation 
and cause steatorrhea. Among patients 3 months after ileostomy closure, Hylander et al. 
(1991) found moderate steatorrhea in approximately 30%, but faecal fat excretion 
normalised with time. Decreased cholesterol absorption, with lower serum total and 
LDL cholesterol and LDL triglycerides has been reported after IPAA (Hakala et al. 
1997a, Hakala et al. 1997b), as have fat-soluble vitamin deficiencies in patients with 
inflammatory bowel disease (Fernandez-Banares et al. 1989, Geerling et al. 1999). 
Reduced vitamin B12 absorption (Schilling test) has been shown in 10 to 30% of 
patients with IPAA, and clinically significant vitamin B12 deficiency has been 
documented in 3 to 9% of such patients (Bayat et al. 1994, M`Koma et al. 1994a, 
M´Koma et al. 1994b).  
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3.4.4. Irritable pouch syndrome 
 
A substantial number of symptomatic patients after IPAA do not meet the criteria for 
either pouchitis or cuffitis (endoscopic and histological inflammation of the rectal cuff). 
These patients can be classified as having irritable pouch syndrome (IPS). There is an 
overlap of symptoms among patients with pouchitis, cuffitis, and IPS. Increased stool 
frequency, urgency, and abdominal cramps are the most common symptoms. A 2002 
study by Shen et al. reported that 46.2% of patients with IPS responded to antidiarrheal, 
anticholinergic, and/or antidepressant therapies. An endoscopic evaluation can 
differentiate among these groups. 
 
3.5. Therapy for pouchitis 
 
3.5.1. Medical therapy 
 
Medical treatment for pouchitis is largely empirical. The hypothesis that faecal stasis 
and bacterial overgrowth may be of importance in the pathogenesis of pouchitis led 
clinicians to treat  patients with antibiotics, and these have become the mainstay of 
treatment, in the absence of controlled trials. 
Most patients with acute pouchitis respond quickly to metronidazole of 1 to 1.5 g/day 
(Hurst et al. 1996, Sagar and Pemberton 1997). This antibiotic reduces leukocyte 
infiltration in the mucosa of the pouch (Kmiot et al. 1993) and faecal bacterial counts of 
Bacteroides. Madden et al. (1994) carried out a double-blind, randomised, placebo-
controlled, crossover trial to assess the efficacy of 1.2 g/day of metronidazole orally in 
11 patients with chronic unremitting pouchitis. Metronidazole was significantly more 
effective than placebo in reducing stool frequency (73% vs. 9%), though without 
improvement in endoscopic appearance and histologic grade of activity. However, 55% 
of metronidazole-treated patients experienced side-effects including nausea, vomiting, 
abdominal discomfort, headache, skin rash, and metallic taste. 
Nygaard and colleagues (1994) administered topical metronidazole (40-160mg/day), 
which induced clinical improvement within a few days without side-effects and with a 
decrease in concentrations of anaerobic bacteria. 
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Shen and colleagues (2001b) treated seven patients with ciprofloxacin at 1 g/day and 
nine patients with metronidazole 20 mg/kg/day for a period of 2 weeks. This study 
showed that both antibiotics were effective and reduced the total PDAI scores and led to 
a significant improvement in symptoms and endoscopic and histologic scores. However, 
ciprofloxacin led to a greater degree of improvement and was better tolerated. 
Recently, budesonide corticosteroid enemas have been shown to be equally effective but 
better tolerated than oral metronidazole in a double-blind controlled trial (Sambuelli et 
al. 2000). While no data have been published on the efficacy of oral 5-ASA, 
uncontrolled studies have suggested that 5-ASA either as suppositories or enemas in 
treatment of acute pouchitis may help (Miglioli et al. 1992). 
Treatment of chronic refractory pouchitis, which includes patients who fail to respond 
to antibiotics and those who continuously relapse once antibiotic treatment ceases, has 
been difficult and disappointing. Among these patients misdiagnosis of Crohn´s disease 
should be excluded. Approximately 5% of IPAA procedures are performed in patients 
whose primary diagnosis of UC is revised at some point after surgery to Crohn´s 
disease. In these cases, therapeutic treatment is the same as for pelvic and perianal 
Crohn´s disease.  
Gionchetti and colleagues (1999) carried out a combined antibiotic treatment in chronic 
treatment-resistant pouchitis. Treating 18 patients who did not respond to a standard 4-
week treatment (metronidazole or ciprofloxacin or amoxicillin/clavulanic acid) orally 
with rifaximin 2 g/day and ciprofloxacin 1 g/day for 15 days. Of these 18 patients, 16 
(88.8%) either improved or went into remission; the median PDAI decreased 
significantly from 11 to 4. A significant decrease occurred in total anaerobes and 
aerobes, enterococci, lactobacilli, bifidobacteria, and bacteroides in faecal samples.  
Mimura and colleagues (2002) treated 44 patients with active or refractory pouchitis 
with ciprofloxacin 500 mg b.i.d and metronidazole 500 mg b.i.d for 4 weeks; 82% went 
into remission, with no serious side-effects noted.  
 
3.5.2. Probiotics 
 
Because of the key role of the intestinal microflora in the development of IBD, 
manipulating this component provides a very intriguing novel approach. Probiotic 
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bacteria are nonpathogenic microorganisms belonging to the normal gastrointestinal 
flora that confer a health benefit by altering the indigenous microflora (Bengmark 1998, 
Fuller 1989). Lactobacilli, bifidobacteria, and other members of the resident microflora 
are commonly selected as probiotics. They can influence intestinal physiology either 
directly or indirectly through modulation of the endogenous ecosystem or immune 
system (Marteau et al. 2001) Preliminary trials of probiotics in maintenance treatment 
of chronic pouchitis are encouraging (Gionchetti et al. 2000a). 
Gionchetti et al. (2000a) demonstrated the effectiveness of the combined probiotic 
preparation VSL#3™ (Yovis:Sigma-Tau, Pomezia, Italy) in preventing flare-ups of 
chronic pouchitis. This product contains 300 billion cells/g of viable lyophilized 
bacteria of four strains of lactobacilli (L. casei, L. plantarum, L. acidophilus, L. 
delbrueckii spp. bulgaricus), three strains of bifidobacteria (B. longum, B. breve, B. 
infantis) and one strain of Streptococcus salivarius spp. thermophilus. In that study, 40 
patients who had achieved clinical and endoscopic remission after one month of 
combined antibiotic treatment (rifaximin 2 g/day + ciprofloxacin 1 g/day) were 
randomised to receive either VSL#3™ 6 g/day or an identical-appearing placebo for 9 
months. All patients who received placebo relapsed (an increase of at least 2 points in 
the clinical portion of the PDAI scoring system). In contrast, 17 of the 20 patients 
treated with VSL#3™ were still in remission at the end of the study. More recently, the 
same probiotic product was also shown to be significantly superior to placebo in the 
prevention of pouchitis onset within the first year after surgery (Gionchetti et al. 
2000b). 
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AIMS OF THE STUDY 
 
 
The aims of the present study were to analyse: 
 
1. factors associated with changes in mucosal morphology after ileal pouch-anal 
anastomosis 
 
2. factors associated with ileal inflammatory activity: previous course of ulcerative 
colitis, extraintestinal manifestations, pANCA level, and smoking habits 
 
3. metabolic consequences in patients with IPAA compared with patients with 
conventional ileostomies, evaluating whether those with IPAA need long-term 
follow-up   
 
4. whether modification of ileal microbial flora by a single strain probiotic bacteria, 
Lactobacillus rhamnosus GG, can ameliorate  inflammation process in patients with 
previous pouchitis history 
 
5. long-term prognosis, and to compare life satisfaction in patients with conventional 
ileostomy with that of patients with ileal pouch-anal anastomosis.  
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PATIENTS AND METHODS 
 
1. Patients 
 
Study subjects were recruited from ileostomy- and IPAA-patient registers from Helsinki 
University Central Hospital. The study was carried out at the Department of 
Gastroenterology in the Helsinki University Central Hospital between January 1997 and 
December 2000. 
The original study population comprised a total 128 study subjects: 107 with ileal 
pouch-anal anastomosis and 21 ileostomy controls. Subjects eligible for study 
participation were those (n= 241), who had undergone restorative proctocolectomy with 
an ileal pouch-anal anastomosis (IPAA) for ulcerative colitis between 1985 and 1994 at 
the Department of Surgery of the Helsinki University Central Hospital. The standard 
operation was a procedure using the two-limbed J-shaped ileal pouch with or without 
covering ileostomy. Invitations were mailed to the 150 consecutive patients living in the 
main catchment area of our hospital, and 110 of them expressed an interest in 
participating. Subjects operated on earlier at the same unit for ulcerative colitis with a 
conventional ileostomy (n= 30), were asked to participate as controls. The diagnosis of 
ulcerative colitis was established in all subjects by standard endoscopic, histological, 
radiological, and clinical assessment, and by proctocolectomy specimens. The clinical 
characteristics of the study population are presented in Table 7. 
This study complies with the Helsinki Declaration, and the study protocol was accepted 
by the Ethics Committee of Helsinki University Central Hospital. 
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Figure 1. Flowchart of patients with IPAA and conventional ileostomy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ulcerative colitis patients with IPAA
 (operated on 1985-1994, n=241) 
Invitations mailed to 150  
consecutive IPAA patients; 110 
interviewed, 107 underwent endoscopy
(Study V)  
Pouchitis, 
LGG-supplementation; 
10 placebo, 10 LGG 
(Study III) 
Analysis of bone density 
(IPAA n=88, IS n=20)  
(Study II) 
Analysis of long-term metabolic
consequences (IPAA, n= 104, 
IS, n=21) (Study I) 
Analysis of medical history;  
15 with optimal outcome, 44 with
history of pouchitis  
Microbial and dietary analysis; 
optimal outcome (n=11), history of 
pouchitis (n=21) 
(Study IV) 
3 excluded for abnormal liver 
function 
Invitations mailed to 30 patients 
 with a conventional ileostomy(IS); 
22 interviewed, 21 underwent  
endoscopy 
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Table 7. Clinical characteristics of study population 
 IPAA Ileostomy 
Total n 107 21 
Sex, M:F 54:53 9:12 
Mean age, yr (range) 45.1 (23 - 69) 51.7 (37 - 68) 
Follow-up, yrs (range) 7.5  (5 - 12 ) 19.2 (16 - 28 ) 
BMI, kg/m2 25.2 ± 1.0  26.3 ± 0.9  
Duration of UC, yrs 6.9 ± 0.6  4.0 ± 1.3  
Extent of UC,         
  pancolitis: left-sided 
 
82:25 
 
20:1 
Indication for surgery,  
  fulminant:chronic 
Dysplasia (%) 
 
21:73 
13 (12) 
 
4:17 
0 
Values presented as number of patients or as means ± SEM 
 
1.1. Study protocol 
 
Study subjects were examined at the out-patient clinic of the Department of 
Gastroenterology at Helsinki University Central Hospital. 
A flowchart of the study subjects during the studies is presented in Figure 1. 
During their first visit, a physical examination was done, and clinical symptoms (stool 
frequency, rectal bleeding, urgency, fever) and medication were recorded. Patients` 
histories were collected: onset and duration of ulcerative colitis (in years); site and extent 
of disease (pancolitis vs. left-sided involvement); indication for IPAA (fulminant, chronic 
active, dysplasia); operation type (one-stage vs. two-stage); and follow-up time after IPAA 
(in years). All subjects completed a questionnaire concerning their overall symptoms 
including smoking habits and satisfaction with life.  
 
2. Methods 
 
2.1. Endoscopic and histological examination 
 
A pouch endoscopy was performed with a flexible endoscope, and findings (edema, 
granularity, friability, loss of vascular pattern, mucous exudate, ulceration) scored from 
0 to 1 each, according to Sandborn et al. (1994b). During the examination of the ileal 
pouch or ileostomy, mucosal biopsies were obtained at four separate sites in the pouches 
and proximal ileum or 10 cm from the orifice of ileostomies. Biopsies were taken from any 
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regions exhibiting active inflammation endoscopically or from normal-appearing mucosa 
in the absence of endoscopic inflammation, avoiding staples and suture lines. 
All biopsy specimens were reviewed in a blinded fashion by one pathologist (AK). 
Serial sections of formalin-fixed paraffin-embedded tissue were stained with 
haematoxylin and eosin (H&E) and high iron diamin-alcian blue (HID-AB). The H&E- 
stained sections were scored on a scale of 0 (absent) to 3 (severe) for degree of acute 
inflammation (polymorphonuclear leukocyte infiltration, ulceration) and for degree of 
villous atrophy by criteria of Moskowitz et al. (1986). The HID-AB stained sections 
were scored for mucin (0=sialomucin only, 1=predominant sialomucin, 2=predominant 
sulphomucin, 3=sulphomucin only). Scores were based on the most severe changes 
evident. The pouchitis disease activity index, PDAI (Clinical symptoms, endoscopic, 
and acute histologic inflammation) as described by Sandborn served to quantify 
pouchitis disease activity. Pouchitis was defined as a PDAI > 7 (Sandborn et al. 1994b). 
On the basis of villous atrophy, the patients with IPAA were divided into three 
subgroups: no villous atrophy or partial atrophy as two groups; but those with subtotal 
or total villous atrophy were considered together as a single group, because of the 
patchy distribution of inflammation and villous atrophy in the pouch (Shepherd et al. 
1987). 
 
2.2. Biochemical assessment 
 
After an overnight fast, immediately after pouch endoscopy all patients had blood samples 
taken for a complete blood count, biochemistry profile, and serum lipid and vitamin 
measurements. Serum concentrations of albumin, calcium, alkaline phosphatase, and 
alanine transferase were measured by standard laboratory methods. Serum parathyroid 
hormone (PTH) (normal 10-60 pg/ml) levels were measured by a commercially available 
two-site immunoradiometric assay (Intact PTH; Nichols Institute Diagnostics). 
Serum total cholesterol and triglycerides were determined by routine hospital methods (kits 
from Boehringer Diagnostica, Germany). 
Vitamin B12 (normal 170-670 pmol/l) and folate (normal 4.4-18.0 nmol/l) were analysed 
by competitive protein binding assay (SimulTRACK radioassay kit by ICN 
Pharmaceuticals, NY, USA)  
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Vitamin A (normal 1.0-2.8 µmol/l) and E (normal 12-40 µmol/l) were determined by high-
pressure liquid chromatography (HPLC), and 25-hydroxyvitamin D3 (normal 20-100 
nmol/l) was determined by radioimmunoassay (DiaSorin Inc., Stillwater, MN, USA). 
A marker of bone formation, serum osteocalcin (normal range, age-dependent: female 
3.8-30, male 11-32 µg/l) was measured with a human-specific two-site 
immunoradiometric assay (IRMA; ELSA-OSTEO, Cis Biointernational, France). A 
marker of bone resorption, the urinary N-telopeptide cross-linked collagen-type 
1/creatinine ratio (U-NTX; normal range: female 5-65 nmol/mmol cretinine, male 5-85 
nmol/mmol creatinine) was measured by enzyme-linked immunosorbent assay (EIA; 
Ostex International Inc, Seattle, WA, USA). 
Determination of perinuclear antineutrophil cytoplasmic antibodies (pANCA) was 
performed by conventional indirect immunofluorescence using ethanol-fixed neutrophil 
slides (Inova Diagnostics, San Diego, CA, USA). A pANCA titre ≥ 1 : 10 was 
considered positive.  
 
2.3. Absorption studies 
 
Absorption of vitamin B12 with intrinsic factor was measured by the Dicopac test 
routinely used at Helsinki University Central Hospital (Bayly et al. 1971). 
Absorption of bile acids was studied by use of the selenenim-labeled synthetic bile salt 
75SeHCAT (taurine conjugate of 23- [75Se]-25-homocholic acid). Ten microcuries of 
75SeHCAT in capsule form was given orally to each patient. Selenium radioactivity was 
measured by whole-body counting with a gamma-camera immediately after ingestion 
and at 3, 24, and 72 hours. Results were expressed as retention of bile acids (%) at three 
days (72 hours), SeHCAT/72h% (normal ≥ 30%). 
 
2.4. Bone mineral density measurements 
 
Bone mineral density (BMD) (g/cm2) was measured by dual energy x-ray 
absorptiometry (DEXA; Hologic QDR 1000, Waltham, MA, USA) at the lumbar spine 
(L1-L4, posteroanterior view) and left femoral neck levels by standard protocols. In the 
present study, results of BMD are expressed as the number of standard deviations from 
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normal values corrected for age and sex (Z score) to better demonstrate any potential 
disease-specific changes after proctocolectomy. Reference values for men and women 
were supplied by Hologic. A Z score < -1 was defined as osteopenia.  
 
2.5. Faecal bile acids 
 
Faecal bile acids were determined from a single stool sample by gas-liquid 
chromatography (Grundy et al. 1965), (HP 5890 series II, Hewlett-Packard, 
Wilmington, DE, USA) on a capillary column (HP-1, Crosslinked Methyl Siloxane, 
length 50 m, diameter 0.32 mm, Hewlett-Packard). Results are expressed as the 
composition of individual bile acids expressed as percentage of total bile acids and µg 
bile acids/g faeces. 
 
2.6. 7-day food diary 
 
Participants recorded their habitual diet for 7 days. They were instructed to record 
everything they ate or drank, using household measures and standard packing units. No 
vitamin or mineral supplement usage was included in diet records. Nutrient and energy 
calculations were based on the Finnish Nutrient Data Bank supplied by the Social 
Insurance Institution Research and Development Centre (Turku, Finland), and carried 
out with use of software for Windows developed at the Research and Development 
Centre. Nutrient values have been derived from analyses of Finnish foods and from 
international food-composition tables. 
 
2.7. Specimens for bacteriologic studies  
 
Fresh faecal samples were collected prior to endoscopy. The pouch was emptied with 
water enemas. During flexible pouch endoscopy before biopsy-taking, the mucosa was 
carefully rinsed with sterile water under direct visual control to remove all possible 
faecal contamination. We obtained five separate tissue biopsy specimens (three for 
bacterial culture and two for histology) from the pouch and five from the afferent limb 
above the pouch. These specimens were taken from the regions exhibiting active 
inflammation endoscopically. Staples and suture lines were avoided. Tissue biopsy 
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samples were thoroughly rinsed with downward jets of sterile saline and placed in a 
Stuart transport tube. 
 
2.8. Analysis of bacteriologic specimens 
 
Bacteriologic samples were immediately transported to the laboratory and processed 
within 2 hours. Specimens were weighed and ground in thioglycolate medium (1:10) in 
a tissue grinder. Faecal samples were homogenised, pH measured (Benchtop 420 pH 
Meter, Orion, USA) and serially diluted (10–1–10–7) in prereduced peptone-yeast extract 
broth (pH 7.0). Appropriate dilutions and aliquots of the homogenates were plated onto 
several selective and non-selective agar media for the isolation of aerobic and anaerobic 
microbes. MRS (deMan Rogosa and Sharpe, Merck) agar was used for the isolation of 
lactobacilli, Brucella agar supplemented with haemin and vitamin K1 for total counts of 
anaerobic bacteria, and blood agar (5% sheep blood) for total counts of aerobic bacteria. 
MRS and Brucella plates were incubated in anaerobic jars filled with a gas mixture 
(80% N2, 10% CO2 10% H2) and blood plates in 7% CO2 atmosphere both at 37°C and 
incubated for up to 14 days. Total counts of the main groups of aerobic and anaerobic 
bacteria and yeast were enumerated. Different colony morphotypes were recorded, 
enumerated, and isolated for further study. Isolates were identified by established 
methods including aerotolerance testing, gram staining, biochemical tests, and enzyme 
profiling (Summanen et al. 1993, Jousimies-Somer et al. 1999). The species and clonal 
identity of selected Lactobacillus GG isolates were confirmed by an arbitrarily primed-
PCR (AP-PCR) method (Tynkkynen et al. 1999). 
 
2.9. Lactobacillus rhamnosus GG supplementation 
 
Subjects were randomised either to treatment with gelatin capsules (Gefilus®, Valio Ltd, 
Helsinki, Finland) containing Lactobacillus rhamnosus GG, 0.5-1 x1010 cfu/capsule, 
with microcrystalline cellulose (MCC)  as a filling material, or to MCC only, as a 
placebo. Each subject received four capsules of Lactobacillus GG per day as two equal 
doses for 3 months. Subjects were asked not to eat probiotic dairy products during the 
supplementation period. 
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2.10. Questionnaire 
 
All subjects completed a questionnaire containing practical questions dealing with 
patients` functional outcome (i.e., stool frequency/24 h, need for night evacuation, use 
of retarding drugs, need for protective pads, soiling, perianal or peristomal soreness, and 
urgency after surgery). Patient satisfaction was evaluated by questions as to overall 
satisfaction (score 1-5), intestinal symptoms (1-4), any restrictions on diet (open 
answer), and social activity, such as changes in social interaction (1-2), occupation (1-
2), or daily activities (1-2). Sexual function: impotence (1-2), retrograde ejaculation (1-
2), dyspareunia (1-2), and smoking and drinking habits were also recorded. 
 
3. Statistical Analysis 
 
All data are expressed as mean ± SEM. Comparisons among the patient groups were 
made by analysis of variance (ANOVA) with the Newman-Keuls test. When variances 
were unequal or distribution was not normal, the Kruskal-Wallis multiple-comparison 
test was used. For comparing IPAA patients to the controls, the Mann-Whitney U-test 
was used. Correlation coefficients between two parameters were calculated with 
Spearman`s rank correlation. A comparison of incidences was performed with χ2 
statistics or Fisher´s exact test. Simple and multiple linear and stepwise regression 
analyses were performed to examine the effects of various independent factors. Any P 
value < 0.05 was considered statistically significant. All statistical analyses were 
performed with NCSS 2000 software for Windows (NCSS statistical software, 
Kaysville, UT, USA). 
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RESULTS 
 
1. Incidence of pouchitis 
 
During the mean 7.5 years (range 5-12 years) of follow-up, 46 (43%) of the 107 IPAA 
patients were treated once or more for clinical symptoms indicating pouchitis. Of the 61 
patients without any acute episode of pouchitis, 16 (26%) achieved by PDAI scoring 
criteria a total score ≥ 7 (range 7-10), indicating ongoing pouchitis. Thus, pouchitis 
occurred in 62 (58%) of the patients during the follow-up period. Of the 107 patients, 15 
(14%) exhibited macroscopic (friability, erythema, ulcers) and/or histologic inflammatory 
changes (PMN cell infiltration, ulcers, atrophy) in the proximal ileum above the pouch. 
This subgroup of patients had the highest inflammatory activity in the pouch as measured 
by PDAI: mean 10.2 ± 0.8 (range 5 - 13), 95% CI 8.5 to 11.9. Ten patients (9.3%) had 
chronic symptoms requiring recurrent antibiotic therapy to keep the pouchitis in 
remission; however, 8 of these had a PDAI ≥ 7 (mean 9.9, range 5-14), indicating 
ongoing pouchitis and suggesting poor response to antibiotics used. Chronic pouchitis 
led to pouch excision in one male patient after his study participation. Of the 107 
patients, 14 (13%) fulfilled our criteria of an optimal outcome: no history of pouchitis, 
no clinical symptoms, normal F/U endoscopies, no ulceration or acute 
polymorphonuclear leukocyte infiltration (PMN) in histological specimens during the 
follow-up. 
 
2. Factors associated with mucosal inflammation 
 
2.1. Previous course of ulcerative colitis 
 
Patients with pouchitis had a significantly shorter disease duration of UC than did those 
without pouchitis before surgery, which suggests their more aggressive and active UC 
inflammation (Study V) (Figure 2). The subgroup of 15 patients with proximal ileal 
involvement had taken a higher cumulative (mean 9.2 ± 1.9; 95% CI 5.1 to 13.3 g 
versus 4.4 ± 0.7; 95% CI 2.8 to 5.9 g, p = 0.07) and daily (mean 8.0 ± 2.5; 95% CI 2.4 
to 13.6 mg versus 2.7 ± 0.9; 95% CI 0.7 to 4.7 mg, p = 0.053) steroid dose than had 
those with optimal outcome (Study IV). No differences between these two subgroups 
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appeared in the type of operation, extent of UC (left-sided/pancolonic) or indication 
(fulminant/chronic active, dysplasia) for surgery. Daily corticosteroid dose in mg of 
prednisone correlated positively with PDAI (r=0.26, p = 0.026) and negatively with age at 
operation (r= -0.25, p = 0.027). In a stepwise regression analysis that included gender, 
age at diagnosis of ulcerative colitis, daily corticosteroid dose in mg of prednisone, 
duration of UC in years, and extent of UC before surgery, the number of acute 
exacerbations of pouchitis was negatively correlated with duration of UC (p = 0.003), 
and with age at diagnosis of UC (p = 0.017). 
 
Table 8. Demographic characteristics of 107 UC patients with ileal pouches 
 Pouchitis,  
N = 62 
No pouchitis 
N = 45 
p 
Sex, M/F 34/28 20/25 0.29 
Mean age, yrs  44.5 ±1.3 46.0 ±1.6 0.30 
Time since IPAA, yrs  7.8 ± 0.3 7.0 ± 0.3 0.05 
Duration of UC, yrs 5.8 ± 0.6 8.8 ± 1.0 0.01 
Extent of UC, pancolitis : left-sided 51/11 31/14 0.10 
Indication for surgery 
  fulminant: chronic 
  dysplasia (%)  
 
15/47 
9 (14) 
 
6/39 
4(9) 
 
0.16 
0.38 
Operation type,  
  one-stage : two-stage 
 
35/27 
 
25/20 
 
0.93 
Number with family history of IBD   
  (%) 
13 (21) 8(18) 0.68 
Number with proximal ileum  
  involvement after IPAA (%) 
15 (24) 0 < 0.001 
Values are numbers of patients or means ± SEM;  
p < 0.05 was considered significant, Mann-Whitney U test, Χ2 -test. 
 
 
Figure 2. Influence of factors in the course of ulcerative colitis on long-term 
outcome after IPAA 
 
 
 
 
 
 
Optimal outcome 
• Longer disease 
duration of UC 
• Lower daily and 
cumulative 
corticosteroid doses
Pouchitis 
• Shorter disease 
duration of UC 
• Higher daily and 
cumulative  
corticosteroid doses 
• Young age 
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2.2. Bacteria 
 
Bacteriological analyses of fresh faecal samples and tissue biopsy specimens were run 
for 21 patients with a pouchitis history (PDAI ≥ 7 in previous follow-up endoscopy), 
and 11 patients with optimal outcome after IPAA.  
The pouches of patients with pouchitis harboured increased concentrations of faecal 
anaerobes and aerobes with trend toward a reduced ratio of anaerobes to aerobes. This is 
reflected in the higher frequency of culture-positive samples of aerobes in patients with 
inflamed pouches than in patients with optimal outcome, who more often harboured 
anaerobic species, especially Bacteroides spp. Concentration of Esherichia coli in faecal 
samples (p < 0.05) and frequency of Esheririchia coli-positive biopsy samples in pouch 
(p < 0.05) and ileum mucosa (p = 0.05) was significantly higher in patients with 
inflamed pouches. No differences existed in Bifidobacterium and anaerobic 
Lactobacillus species between these groups. The main differences between the groups in 
total anaerobes and aerobes are presented in Table 9, and frequencies of bacteria for 
study groups in Table 10. 
 
Table 9. Microbiological assessment of tissue and faecal samples from patients with 
normal (n=11) and inflamed (n=21) pouches 
 
 Log10  CFU/g Optimal 
outcome 
n = 11 
95% CI Pouchitis 
n = 21 
95% CI p 
Proximal ileum      
   Total anaerobes 3.7 ± 0.3 3.0 – 4.4 4.1 ± 0.2 3.7 – 4.5 0.41 
   Total aerobes 2.9 ± 0.1 2.6 – 3.1 3.1 ± 0.2 2.7- 3.5 0.57 
Pouch mucosa      
   Total anaerobes 4.1 ± 0.3 3.4 – 4.8 4.0 ± 0.2 3.5 – 4.4 0.65 
   Total aerobes 3.1 ± 0.2 2.5 – 3.6 3.4 ± 0.2 3.0 – 3.8 0.18  
Faeces      
  Total anaerobes  8.7 ± 0.2 8.2 – 9.2 9.4 ± 0.1 9.2 – 9.7 0.007 
  Total aerobes 7.0 ± 0.3 6.4 – 7.6 8.0 ± 0.2 7.6 – 8.3 0.007 
  Total anaerobes/ 
   aerobes 
 1.3   1.2   0.14 
Mean count expressed as log10 CFU per gram of tissue ± SEM. 
p < 0.05 was considered significant, Mann-Whitney U-test. CI: confidence interval 
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2.3. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) 
 
The prevalence of pANCA in 107 IPAA patients was 30% (n = 32), and 28% in the 21 
patients with conventional ileostomies. Of IPAA patients, 10 had high serum pANCA 
levels (> 100): 8 of these had pouchitis (PDAI ≥ 7, p = 0.036). In patients with high 
pANCA levels, the mean PDAI score was significantly higher 8.7 ± 1.2 than in patients 
with low ≤ 100 (mean PDAI 6.0 ± 0.8) or those with negative levels (4.9 ± 0.9, p = 
0.019).   
 
2.4. Extraintestinal manifestations (EIMs) 
 
EIMs were present before restorative proctocolectomy in 27 (25%) of the 107 IPAA 
patients, of whom 5 had more than one EIM (Table 11). Peripheral arthritis was the 
most common manifestation, and no differences appeared in rates of EIMs by sex. 
Analysis of patients with preoperative EIMs demonstrated that EIMs were a significant 
determinant of pouchitis disease activity. In particular, an increased risk for pouchitis 
occurred in patients with pre-operative ankylosing spondylitis (AS) or iritis: Of 14 such 
patients, 12 (86%) had pouchitis (PDAI ≥ 7); OR 11.4 (95%CI 2.3-39.3), p < 0.001. 
One patient had both pre-operative complications. 
 
Table 11. Prevalence of pouchitis in patients with history of extraintestinal manifestations 
(EIMs) before surgery for ulcerative colitis 
 
EIM N Number of patients 
 with PDAI ≥ 7 (%) 
OR (95% CI) p 
All EIMs 27 16 (59) 2.7 (1.1–6.4)  0.03 
  PSC 2 1 (50) 1.4 (0.1-14.3) 0.80 
  AS/ Sacroileitis 8 7 (88) 11.7 (1.4–50.4) 0.006 
  Peripheral arthritis 13 4 (31) 0.60 (0.2–3.5) 0.34 
  Iritis 7 6 (86) 9.8 (1.2–43.4) 0.013 
  Erythema nodosum 3 1 (33) 0.70 (0.1–6.6) 0.78 
PSC, primary sclerosing cholangitis; AS, ankylosing spondylitis; OR, odds ratio; CI, confidence interval, 
χ2 –test 
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2.5. Smoking 
 
Smoking data were collected by questionnaire, or direct interview, or both. Current 
smokers showed a trend toward lower inflammatory activity and prevalence of pouchitis 
(Table 12). 
 
Table 12. Smoking habits, inflammation activity, and  
           prevalence of pouchitis (PDAI ≥ 7) 
 
    
 Number PDAI∗ Pouchitis %∗∗ 
Non-smoker 40 6.6 ± 0.6 50 
Ex-smoker 36 4.9 ± 0.6 41 
Smoker 31 4.6 ± 0.7 29 
Values presented as number of patients or as means ± SEM 
 ∗p= 0.07, (ANOVA), ∗∗p= 0.23 (χ2 –test) 
 
 
 
In a stepwise regression analysis that included sex, age, time since IPAA surgery, extent 
of UC before surgery, smoking habits, serum pANCA level, and occurrence of EIMs, 
pouchitis disease activity (PDAI) was correlated positively with serum pANCA levels 
(p = 0.005) and EIMs (p = 0.01), but negatively with smoking habits (p = 0.04). 
 
 
3. Factors associated with mucosal morphology 
 
3.1. Villous atrophy 
 
Villous atrophy correlated positively with inflammatory activity (PDAI) (r= 0.67, 
p<0.001) and with number of total faecal anaerobes (r= 0.45, p= 0.01) and aerobes (r= 
0.30, p= 0.09). All 21 patients with a conventional ileostomy showed normal villous 
architecture and had no inflammation. In stepwise and multiple regression analysis, 
number of pouchitis episodes and acute inflammation (infiltration of neutrophils) in the 
mucosa were both statistically significant predictors of the presence of villous atrophy. 
No correlation existed between degree of villous atrophy and age, sex, follow-up time, 
BMI, or smoking.  
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3.2. Colonic metaplasia 
 
Some degree of sulphomucin in mucin staining occurred in 54 (50%) of 107 IPAA 
patients.  
Associations between bacteria, dietary factors, faecal bile acids, and mucosal 
morphology were studied in 21 IPAA patients with pouchitis and in 11 patients with 
optimal outcome. Of 32 patients, 14 showed sulphomucin predominance. No 
differences existed in mean nutrient intake, composition of faecal bile acids, or 
microbial cultures of tissue biopsy between groups with and without pouchitis. Degree 
of colonic metaplasia was positively associated with faecal anaerobic (r= 0.44, p= 0.01) 
and aerobic flora (r= 0.42, p= 0.02). Low intake of lactose was associated with 
sulphomucin predominance. A negative correlation existed between faecal aerobes and 
dietary lactose consumption (r = -0.45, p= 0.02) (Table 13). 
 
 
Table 13. Clinical characteristics of 32 IPAA patients with sialomucin or sulphomucin       
                predominance 
 
 Mucin predominance p 
 Sialomucin (n = 18) Sulphomucin (n = 14)  
Sex, M/F 9/9 9/5 0.42 
Time since IPAA, yrs 8.4 ± 0.6 8.8 ± 0.7 0.67 
Duration of ulcerative colitis,   
  yrs 
8.0 ± 1.5 6.6 ± 1.5 0.58 
PDAI 3.4 ± 0.9 7.6 ± 1.0 0.01 
Subtotal/ total villous atrophy  
  (%) 
2 (11) 9 (64) 0.004 
Bacteria, Log10  CFU/g of tissue    
     Faecal anaerobes 8.9 ± 0.16 9.6 ±  0.14 0.007 
     Faecal aerobes 7.4 ± 0.22 8.0 ± 0.23 0.07 
Diet    
   Dairy products (g) 327 ± 58 155 ± 38 0.04 
   Lactose (g) 16.7 ± 2.9 8.0 ± 1.9 0.02 
Faecal bile acids    
   Cholic acid (CA) 43.0 ±7.8 37.9 ± 4.3 0.56 
   Chenodeoxycholic acid      
    (CDCA)                       
17.2 ± 3.0 23.9 ± 2.1 0.07 
   Deoxycholic acid 7.8 ± 5.0 5.5 ± 2.0 0.71 
   Lithocholic acid 1.7 ± 1.0 2.0 ± 0.8 0.43 
Values presented as means ± SEM, P < 0.05 was considered significant, Mann-Whitney U test. 
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In a logistic regression analysis that included sex, time since surgery, number of total 
faecal aerobes and anaerobes, dietary fibre, intake of lactose, and primary bile acids, 
sulphomucin predominance (colonic metaplasia) was positively correlated with total 
faecal anaerobes (p = 0.03), and negatively with lactose intake (p = 0.03).  
 
4. Effect of Lactobacillus GG supplementation on pouch microbial 
flora and inflammation 
 
Twenty patients (10 LGG, 10 placebo) with a previous history of pouchitis and 
endoscopic inflammation received Lactobacillus GG in gelatin capsules (0.5-1 x 1010 
cfu/capsule) or placebo, two capsules b.i.d for 3 months. Lactobacillus GG 
supplementation balanced the pouch intestinal flora by increasing the ratio of faecal 
total lactobacilli to total faecal anaerobes (p = 0.03), to total faecal aerobes (p = 0.02), 
and increasing the frequency of lactobacilli-positive cultures in pouch and afferent limb 
mucosa biopsy samples. However, only 40% of the patients were colonised with the 
Lactobacillus GG. No differences appeared between the groups in the PDAI score or in 
faecal or tissue biopsy samples of total anaerobes or aerobes. The effect of 
Lactobacillus GG supplementation on inflammation activity is presented in Fig 3. 
 
 
Figure 3. PDAI scores before and after Lactobacillus GG (LGG) or placebo  
                supplementation 
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5. Factors associated with long-term metabolic consequences  
 
5.1. Villous atrophy 
 
A significant change toward lower absorption of bile acids, and lower serum levels of 
lipids, fat-soluble vitamins, and albumin occurred in patients with subtotal to total 
villous atrophy. The effect of villous atrophy on absorption studies and on long-term 
haematological and metabolic consequences is presented in Tables 14 and 15.  
Prevalence of osteopenia (Z-score < -1) was 32%, but severe osteopenia or osteoporosis 
(Z < -2) was uncommon, found in only 2.3 % of IPAA patients. Those with osteopenia 
were significantly younger (mean age 33.5 yr ± 1.9; 95% CI 29.4 to 37.6 versus 40.9 yr 
±  1.3; 95% CI 38.3 to 43.5) and had a lower body mass index (21.8 kg/m2 ± 0.8; 95% 
CI 20.4 to 23.2 versus 24.9 kg/m2 ±  0.5; 95% CI 23.7 to 26.1) at the time of the 
operation than did those with normal bone density. No differences appeared in mean 
cumulative or daily steroid dose. Effect of villous atrophy on bone mineral density at 
the lumbar spine and femoral neck is presented in Fig 4.  
 
Figure 4. Lumbar spine (L1-L4) and femoral neck BMD Z scores in ileostomy patients (n=20) 
and in IPAA patients with normal villous structure (n=14), partial (n=47), or sub-/total villous 
atrophy (n=27). Means (± SE) of Z scores. P∗ = 0.02 compared to patients with normal villous 
structure. 
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5.2. Extent of inflammation in the remaining ileum 
 
 
Patients with inflammation in the proximal ileum (n=14, Study I) displayed the lowest 
serum total cholesterol (mean 3.8 mmol/l ± 0.3, p < 0.001), LDL (mean LDL 2.0 mmol/l ± 
0.2, p= 0.002), and HDL (mean 1.4 mmol/l ± 0.1, p= 0.009) levels compared to levels of 
controls and patients with normal pouch morphology. Moreover, they showed the highest 
prevalence of osteopenia (66.7%) and the lowest spine (mean – 0.89 ± 0.36, p= 0.006) 
and femoral neck (mean –0.63 ± 0.29, p= 0.07) Z scores. 
 
6. Long-term functional outcome and patient satisfaction 
 
A great majority of patients (90%) in both study groups were satisfied (Table 16). 
However, patients with IPAA tended to have daily more often intestinal symptoms. 
Occasional incontinence was reported by 55% of IPAA patients; 25% of these needed 
protective pads. 
 
Table 16. Prevalence of symptoms, changes in daily social activities, sexual function,  
and dietary restrictions in patients with conventional ileostomy (n = 21) and with  
IPAA (n = 104) 
 
Variable Ileostomy (%) IPAA (%) p 
Overall satisfaction 19 (90) 93 (89)  
Intestinal symptoms 
     no symptoms 
     occasionally 
     daily/ severe 
 
13 (62) 
7 (33) 
1 (5) 
 
40 (39) 
42 (41) 
21 (20) 
 
 
 
0.09 
Social activity 
   changes with social interaction 
   avoidance of special social happenings  
   change in work 
                   hobbies 
                   travelling  
 
6 (29) 
18 (86) 
3 (14) 
6 (29) 
5 (24) 
 
16 (15) 
33 (32) 
14 (14) 
16 (16) 
26 (25) 
 
0.15 
<0.001 
0.95 
0.15 
0.89 
Sexual function 
    impotence 
    retrograde ejaculation 
    dyspareunia 
 
2 (22) 
1 (11) 
3 (30) 
 
7 (14) 
3 (6) 
10 (21) 
 
0.50 
0.55 
0.55 
Dietary restriction 6 (29) 30 (29) 0.99 
Values are presented as numbers, p < 0.05 was considered as significant, Χ2 –test 
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DISCUSSION 
 
1. Incidence of pouchitis 
 
The main complication after restorative proctocolectomy with ileal pouch-anal 
anastomosis remains pouchitis. The latest reported rates of incidence of pouchitis in 
patients operated on for ulcerative colitis range from 29 to 59% (Simchuk et al. 2000, 
Heuschen et al. 2001a). Our rate of pouchitis of 58% falls within this range.  
To minimise selection bias, the present study population comprised of consecutive 
patients operated on for ulcerative colitis between the years 1985 and 1994 at the 
Department of Surgery of Helsinki University Central Hospital. Of 150 invited patients 
living in the main catchment area of our hospital, 110 expressed their interest in 
participating. Those willing to participate in any such study may have more symptoms, 
in this case a higher inflammation score. However, a recent study by Shen et al. has 
shown that 25% of patients with a high symptom score suggestive of pouchitis did not 
fulfil criteria for the diagnosis of pouchitis as measured by PDAI. In addition, 
endoscopic and histologic inflammation are not always associated with the presence of 
severe symptoms (Luukkonen et al. 1994, Shen et al. 2001a), a finding compatible with 
the present findings. Of patients without any pouchitis history, 26% had significant 
endoscopic and histologic inflammation and achieved a PDAI score of 7 or higher, 
indicating active pouchitis. This finding compares well with that of Shen et al. (2001a), 
who reported that 36% of patients with only mild symptoms not typically suggesting the 
diagnosis of pouchitis had PDAI ≥ 7. Thus, a combination of symptoms and endoscopic 
and histologic evaluations should always be pursued for accurate diagnosis of pouchitis. 
For a considerable number of patients, defining pouchitis merely on the basis of clinical 
symptoms would mean a risk of overlooking chronic undetected inflammation. This 
suggests the need for long-term surveillance of all patients with IPAA, as proposed by 
Shepherd (1990). If patients are seen only on a nonroutine basis, only when 
experiencing symptoms of pouchitis, pouchitis incidence would seem unrealistically 
low. 
Although the number of control subjects with conventional ileostomies was limited, and 
they underwent surgery before the era of IPAA, and were of higher mean age with a 
longer follow-up time, in all of them, prestomal ileal mucosa was normal. 
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2. Severity and extent of inflammation 
 
The pouchitis disease activity inflammation (PDAI) score allows differentiation only 
between “no pouchitis” (< 7 points) and “pouchitis” (≥ 7 points). This strict criterion 
may be misleading, because inflammation activity varies greatly among patients and is 
not an “on-off” phenomenon. Active and chronic inflammation may still exist in the 
majority of those with PDAI < 7, “no pouchitis”. Some degree of pathological 
inflammation can be found endoscopically and histologically in almost every pouch. 
This low inflammation activity has been seen as an adaptive inflammation, because it is 
almost universal (Heuschen et al. 2001a). It is suggested that this form of inflammation 
has little or no impact on a patient´s well-being and long-term outcome after IPAA. 
However, Thopmson-Fawcett and colleagues presented a case of a 37-year-old woman 
who had dyplasia with inflammation activity at only a low acute and chronic level 
(Thompson-Fawcett et al. 2001).  
An optimal outcome with no inflammation appeared in 13% of our IPAA patients after 
a mean 7.5-year follow-up. This subgroup of patients had a slightly longer disease 
duration of UC, and their cumulative dose of corticosteroid used before colectomy was 
lower, suggesting a more benign disease course. 
The high inflammatory activity with proximal ileal involvement in 14% of our patients 
suggests ongoing chronic active pouchitis. A major concern in this subgroup of 15 
patients is the risk for unrecognised Crohn´s disease. These patients showed the highest 
pouch-inflammation levels in our study. Inflammatory activity in the proximal limb was 
restricted, usually distally to less than 10 cm above the pouch junction. Endoscopically, 
no deep ulcers or granulomas in histological specimens were evident, suggesting that 
inflammatory activity in the proximal limb occurs as a manifestation of chronic primary 
pouchitis rather than indicating a misdiagnosis of the original disease process. 
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3. Factors associated with severity of inflammation 
 
3.1. Previous course of ulcerative colitis 
 
The extent of preoperative UC in the colon was not a risk factor for development of 
pouchitis. In previous studies this question has aroused controversy. Our data parallel 
those of Samarasekera et al. (1996), who found no relationship between distal colitis or 
more extensive disease and frequency of pouchitis. In contrast, Schmidt et al. (1998) 
reported that the colonic extent of the disease had a significant association after IPAA 
with subsequent development of pouchitis; severity of the UC pre-operatively was not 
predicive for pouchitis, unlike in our findings (Figure 5). 
 
Figure 5. Factors associated with postoperative ileal inflammation activity in pouches 
 
 
 
 
 
 
 
 
 
 
 
Our data show (Studies II, III, V) that the severity of the post-operative inflammatory 
process is associated with severity of the UC. Patients with pouchitis had a significantly 
shorter disease duration of UC than did those without pouchitis. Their pre-operative 
cumulative and daily corticosteroid doses had been significantly higher, suggesting 
inflammation activity 
0 18 
smoking 
EIMs, IL-1Ra, HLA
 
pANCA
previous course of UC; 
•disease duration 
        •corticosteroid dose 
 normal                       mild                         moderate                       severe 
       ↓   B a c t e r i a l   o v e r g r o w t h   ↑
PDAI 
                                                                                          63                                                                         
 
 
more aggressive and active UC inflammation. It is possible that such patients are 
immunologically or genetically more susceptible to ulcerative colitis and thus to 
pouchitis than are those with an optimal outcome (Study II). Carter and colleagues 
(2001) reported that the interleukin 1 receptor antagonist gene allele 2 predicts pouchitis 
after IPAA in ulcerative colitis. 
Our patients with extraintestinal manifestations before surgery had about a 3-fold risk 
for developing pouchitis. Pouchitis (PDAI≥ 7) occurred in 59% of the patients at risk, a 
finding comparable to findings of studies reporting a prevalence of pouchitis of 61% to 
64% in patients with EIMs (Lohmuller et al. 1990, Penna et al. 1996). Studies have 
revealed that factors leading to active inflammation show an overlap among IPAA, UC, 
and EIMs. In ulcerative colitis, a strong association has been described between disease 
behaviour and HLA allelic variation. It has become apparent that the HLADR B1∗0103 
allele may predict severity of UC, need for surgery, and presence of EIMs involving the 
joints, skin, and eyes (Roussomoustakaki et al. 1997, Orchard et al. 2000). HLA 
associations with primary sclerosing cholangitis (PSC) also exist: the HLA-B8/DR3 
haplotype is frequent in patients with UC with PSC but infrequent in patients with UC 
without PSC (van Milligen de Wit et al. 1995). 
 
 
3.2. pANCA 
 
In UC, pANCA expression is associated with distinct clinical phenotypes, including 
treatment-resistant left-sided disease (Sandborn et al.1996), aggressive disease course 
(Vecchi et al. 1998), and a need for surgical intervention early in the disease course 
(Boerr et al. 1995). Here we show that, of those with high pANCA levels (> 100) after 
colectomy, 80% have pouchitis. Studies examining the correlation between pANCA 
expression and pouchitis have been contradictory. Yasuda et al. (1998) found no 
significant difference in pANCA expression between patients with or without pouchitis. 
Sandborn et al. (1995) found a frequency of pANCA in patients with chronic pouchitis 
of 100% compared with only 50% in patients without pouchitis. A recent study by 
Fleshner et al. (2001) showed that a high level of pANCA before colectomy was 
significantly associated with development of chronic pouchitis. Produced by mucosal B-
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cells, pANCA reflects a disease activity-associated immune response; the 
immunoreactive protein epitopes are expressed by colonic bacteria (e.g., Bacteroides 
caccae, Escherichia coli) (Cohavy et al. 2000). It is possible that patients with high 
levels of pANCA are predisposed to develop a more vigorous immune response to 
bacterial products. 
 
 
3.3. Smoking 
 
Current smokers had a lower prevalence of pouchitis (29% vs. 50%) than did non-
smokers. In a regression analysis model smoking was negatively correlated with 
inflammatory activity. This finding agrees with that of Merret et al. (1996) who found, 
after IPAA for UC, a strongly protective effect for current cigarette smoking against the 
development of pouchitis. It appears that the effect of smoking on pouchitis parallels 
that seen in UC (Thomas et al. 1998). What component of cigarette smoke is beneficial 
is unclear.  
 
3.4. Bacteria 
 
The most dramatic finding concerned total counts in faecal bacterial samples from 
patients with pouchitis, which were significantly higher than those noted in the group of 
patients with an optimal outcome. This finding differs from earlier findings in subjects 
with optimal outcome or good results compared with subjects suffering inflammation. 
Sandborn et al. (1995) and O´Connell et al. (1986) reported no differences in anaerobic 
or aerobic bacteria between patients with and without pouchitis. Ruseler-van Embden et 
al. (1994) found an increased number of total faecal aerobes (p= 0.03) but no difference 
in anaerobes. As no prior antibiotic medication was allowed, and none of our subjects 
were examined during any acute exacerbation of pouchitis, we thus assume that the 
microbial and morphological changes we found represent a stable and long-term 
condition in the pouch. 
The diversity of isolated bacteria was high both in faecal and in mucosal biopsy samples 
with no differences found in mucosal concentrations of bacteria. Species isolated from the 
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mucosa were all of faecal origin, and the main anaerobic microorganism isolated from the 
mucosa was Bacteroides. The main aerobes were primarily E. coli. Similar to findings of 
Ruseler-van Emden et al. (1994), we found a trend toward a decreased ratio of 
anaerobes to aerobes in those with a history of pouchitis. This is reflected in the 
significantly higher concentration of E. coli in faecal samples, and in higher frequency 
in mucosal samples in patients with inflamed pouches than in those with an optimal 
outcome. 
These findings are in parallel with Swidsinski et al. (2002), who reported high 
concentrations of Bacteroides and E. coli in mucosa biopsy samples in patients with 
active ulcerative colitis and Crohn´s disease. 
Many investigators have studied adhesive E. coli in IBD in humans. Based on an in-
vitro adherence assay to epithelial cells, adhesive E. coli strains were found to be 
significantly more frequent in patients with IBD than in healthy controls, leading to the 
assumption that E.coli adherence may be a primary importance rather than arising 
secondary to the disease (Giaffer et al. 1992, Darfeuille-Michaud et al. 1998). However, 
serotyping data and analysis of genetic virulence markers of mucosal E. coli showed 
wide variability among mucosal E. coli strains, which speaks against a single E. coli 
pathogen´s being responsible (Swidsinski et al. 2002). 
Our microbial findings for faecal and tissue biopsy samples suggest that the total load of 
luminal bacterial flora, the faecal stream, and exposure to bacteria all play important 
roles in the aetiology of pouchitis. However, the high diversity of bacterial flora without 
a predominance of a single microorganism speaks against a specific pathogen´s being 
the cause. It is evident that a specific host response, resulting from peculiarities of 
immunity, genetic disposition, or symbioses-like interaction, plays an important role in 
the aetiology of pouchitis.  
 
4. Effects of Lactobacillus rhamnosus GG on ileal-pouch inflammation 
 
In our study, a single-strain Lactobacillus rhamnosus GG administered in two gelatin 
capsules (0.5 – 1 x 1010 cfu/capsule)  b.i.d. for 3 months balanced faecal bacterial flora 
by elevating the ratio of total lactobacilli to total anaerobes and aerobes but was 
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inefficient as a primary therapy for clinical response. No differences appeared in the 
mean inflammation activity before or after supplementation.  
In animal models, the effects of lactobacilli on intestinal inflammation have been 
controversial. Madsen et al. (1999) have shown that Lactobacillus sp. reduced levels of 
colonic mucosal adherent and translocated bacteria and attenuated development of 
colitis in interleukin 10 gene-deficient mice. A recent study by Holma and colleagues 
(2001) showed that Lactobacillus rhamnosus GG did not affect the severity of acute 
acetatic acid-induced colitis in the rat. 
Lactobacillus GG was recovered in the faecal flora in 40% of the cases, but was not 
found in mucosal biopsies. No single factor predicting survival existed in a stepwise 
regression analysis. It is, however, evident that the fast transit time, high stool frequency 
(mean 7/day in our study), watery stool, and changes in mucosal morphology (villous 
atrophy) may disturb the adherence and colonisation of probiotic bacteria. As 
Lactobacillus GG is adherent to intestinal mucus, the bolus of bacteria ingested in 
capsules may be washed out, together with ileal secretions. It is evident that in patients 
with ileal-pouches, higher doses of probiotics may be needed for probiotics`intestinal 
survival when administration is in freeze-dried form.  
 
 
5. Consequences of bacterial overgrowth and inflammation 
 
5.1. Mucosal morphology 
 
A mucosal biopsy specimen from normal functioning pouches after IPAA shows villous 
atrophy, crypt hyperplasia, and change in mucin type from sialomucin to sulphomucin. 
These changes have been interpreted as an adaptation of the ileal mucosa to luminal 
changes (Moskowitz et al. 1986). In the present study, villous atrophy was strongly 
associated with inflammation activity in the pouch. Subtotal to total villous atrophy 
occurred most often in patients with chronic active pouchitis. Thus, in long-term follow-
up, villous atrophy can be viewed as a simple marker of inflammatory activity rather than 
as an adaptive response in the pouch. In the long term, this may be important, because both 
chronic pouchitis and villous atrophy are connected to an increased risk for development of 
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dysplasia (Gullberg et al. 1997). However, the latest data so far suggest that development 
of dysplasia in ileal pouches is probably a rare event (risk < 0.05%) within 15 to 20 years 
of pouch surgery (Thompson-Fawcett et al. 2001). 
A significant change in mucin staining towards a more colonic type of sulphomucin 
occurred in our patients with a pouchitis history, a finding closely similar to that of 
earlier studies (Shepherd et al. 1987, De Silva et al. 1991b, Luukkonen et al. 1994). The 
mechanisms underlying colonic metaplasia are likely to be influenced by interaction 
between bacteria, SCFA, and bile acids.  
A novel finding was that our patients with sulphomucin predominance showed a trend 
toward reduced daily intake of dairy products. It is said that cross-sectional studies 
evaluating current diet are of little value, as nutritional habits are already influenced by 
the illness itself. Most of the patients reported, however, that they had continued their 
usual diets after colitis surgery. 
Lactose intake, reflecting consumption of dairy products, was significantly inversely 
correlated, in a multiple and logistic regression analysis, with sulphomucin 
predominance. Our study sample is small, but this association is interesting, because 
lactose has been seen as a potential prebiotic factor. In inflammatory bowel disease, 
lactose may promote growth of the lactic acid-producing bacteria and thus prevent the 
expansion of potential pathogens (Szilagyi 2002). We found a negative correlation 
between lactose and faecal aerobes. Earlier studies have shown that regular lactose 
consumption in dairy products causes a trend toward lower levels of intestinal microbial 
flora (Ito and Rimura 1993). 
 
3.2. Is pouchitis a metabolic problem? 
 
We have shown that patients with IPAA more often have metabolic consequences than 
do patients with conventional ileostomies, who preserve their normal villous 
architecture and have no inflammation. Chronic and acute inflammation with ulceration 
in the pouch leads to villous atrophy and to loss of absorptive capacity and changes in 
pouch permeability and ileal function. These changes are associated with metabolic 
consequences.  
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Although hypoalbuminemia was rare (< 5%), serum albumin concentration presented a 
significant inverse correlation with inflammatory activity. Hypoalbuminemia is a very 
common finding in IBD, and results predominantly from intestinal protein loss and 
increased catabolism. Serum albumin is merely a marker of disease activity rather than 
of nutritional status (Geerling et al. 1999). 
Our findings confirm the results of a study by Hakala et al. (1997), who reported 
impaired cholesterol absorption after IPAA. In long-term follow-up, however, lower 
lipid concentrations are evident, especially in patients with recurrent or chronic 
pouchitis and villous atrophy. Among our patients after IPAA, although vitamin D 
deficiency appeared in 10.6%, we were unable to demonstrate any significant correlation 
between serum 25(OH)D3 and inflammation activity, villous atrophy, or bile acid 
absorption. The common use of multivitamins by the study subjects may be a confounding 
factor. 
IPAA patients with subtotal to total villous atrophy have a higher prevalence of 
osteopenia than do subjects with normal villous structure. Our prevalence of osteopenia 
(32%) compares with earlier findings in IBD patients, although severe osteopenia or 
osteoporosis (Z score < -2) was uncommon, found in only 2.3% of IPAA patients. This 
may represent recovery of bone density after surgery for ulcerative colitis. The recent 
longitudinal study by Abitbol et al. (1997) showed a positive change in bone density at 
the spine (+2.3%) and femoral neck (+2.1%) during a mean 28-month follow-up after 
proctocolectomy for ulcerative colitis. In our subjects with a conventional ileostomy, 
normal villous architecture was preserved, but lumbar spine osteopenia was common 
(prevalence 30%) among them. One limitation of the present study was that patients 
with conventional ileostomy were significantly older, and the prevalence of 
postmenopausal women was the highest (35%), among all groups. 
Inflammatory activity is usually restricted to the pouch, only occasionally rising into the 
proximal limb. Thus, the risk for developing hypoalbuminemia or hypovitaminosis 
seems to be less frequent in patients with IPAA than in patients with active 
Crohns´disease or ulcerative colitis. However, those patients with proximal ileum 
involvement are at significantly increased risk for long-term metabolic consequences. In 
them, pouchitis may be a metabolic problem. 
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4. Life after colectomy 
 
The clinical and functional results after UC and conventional ileostomy and ileal pouch-
anal anastomosis are well known: both are safe, both incur moderate morbidity, and 
both are efficacious. Quality of life following surgery for ulcerative colitis is excellent 
in most patients. Although the pelvic pouch procedure has become the choice for most 
patients, those with a conventional ileostomy appear to have an excellent quality of life, 
as well. This was evident also in our study. In terms of overall satisfaction, the patient 
groups were similar: 90% of conventional ileostomy and 89% of ileal pouch-anal 
anastomosis patients stated that they were satisfied. Limitations in work, diet, hobbies, 
and sexual life were equal in both groups. The most significant difference was that 86% 
of ileostomy patients reported an avoidance of special social happenings. Such 
happenings were not specified in the questionnaire. A shortcoming of our study was the 
questionnaire, which was non-validated, and the small number of control patients. 
However, our data compare well with those of other studies. Kohler et al. (1991) from 
the Mayo Clinic surveyed 406 patients who had a conventional ileostomy, 403 patients 
with a Koch pouch and 300 with a pelvic pouch and reported more than 90% in each of 
the three groups to be satisfied with their current status; more than 90% had returned to 
work. These patients were also similar in their ability to take part in social and 
recreational activities and sports, perform housework, enjoy family relationships and 
sexual activity, and travel. Jimmo and Hyman (1998) studied 12 patients with a 
conventional ileostomy and 55 with a pelvic pouch procedure. Overall, 83% of patients 
with a pelvic pouch and 83% with a conventional ileostomy were satisfied with the 
procedure. When patients completed the IBD questionnaire (IBDQ), no significant 
differences appeared between these two groups in overall score or by category. 
 
7. What are we really saving? 
 
Restorative proctocolectomy with ileal pouch-anal anastomosis was developed in an 
attempt to eliminate the need for a permanent stoma, to preserve the patients´ body 
image, and thus to improve quality of life. However, our data and earlier reports show 
that in both operation groups over the long-term, quality of life was equal. Both 
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operations for treatment of ulcerative colitis have their advantages and their 
disadvantages and risks. The pouchitis syndrome is a major drawback after surgery. It is 
a bacteria-mediated disease in patients immunologically or genetically susceptible to 
UC. In the presence of bacterial overgrowth in the pouch, mechanisms involved in the 
etiopathogenesis of ulcerative colitis will strike back, leading to chronic pouchitis. Thus, 
considering only inflammation mechanisms, ileal pouch-anal anastomosis is a non-
rational operation. Long-standing chronic mucosal inflammation in the gut with a small 
risk for neoplastic transformation have to be taken into consideration. Patients with 
chronic pouchitis will need long-term follow-up, and long-term medical treatment in 
lieu of a permanent ileostomy.  
Patients who require surgery for ulcerative colitis have several options available. 
Considering postoperative morbidity and quality of life aspects, each operation should 
be carefully considered, and the pro and cons discussed in detail with the patient and his 
or her family. 
 
 
8. Recommendations for long-term follow-up. 
 
Clinically, this study suggests that patients with extraintestinal manifestations and high 
level pANCA should be counselled on their high risk for developing chronic pouchitis 
after surgery. Of all cases of pouchitis in UC, 80 to 90% occur during the first 5 years 
after construction of the IPAA (Luukkonen et al. 1994, Heuschen et al. 2001). 
Cumulative risk of pouchitis ranges from 47 to 59% after 10 years following surgery. 
Absence of clinical symptoms, as shown also in the present study, is not a safe marker 
for absence of pouchitis. 
According to previous and the present data, it is obvious that all patients should be re-
evaluated 5 years after proctocolectomy to diagnose also those who have developed a 
silent, asymptomatic chronic inflammation. A limitation at the present time is the lack 
of any standard recommendations for long-term follow-up in the literature. I agree with 
Heuschen and colleagues at the University of Heidelberg who recommend standard 
long-term follow up after 5 years at 2-year intervals. Patients with chronic pouchitis 
should be surveyed in an intensified follow-up program.  
                                                                                          71                                                                         
 
 
SUMMARY AND CONCLUSIONS 
 
The aim of the present study was to study the long-term outcome after restorative 
proctocolectomy with ileal pouch-anal anastomosis, the factors associated with mucosal 
morphology and inflammation, and the influence of Lactobacillus rhamnosus GG on 
ileal inflammation and the microbial flora. Patients with conventional ileostomies 
served as a control group.  
The main findings were as follows. 
 
• Both villous atrophy and colonic metaplasia were positively associated with faecal 
anaerobic and aerobic flora. Villous atrophy can be seen as a simple marker of 
inflammatory activity in long-term follow-up. All patients with conventional 
ileostomies had normal mucosal morphology without inflammation. 
 
• The incidence of pouchitis was 58% with increased risk for pouchits in patients with 
extraintestinal manifestations before surgery and high pANCA levels after surgery. 
Current smokers tended to show a more benign disease course. Patients with 
pouchitis harboured significantly higher faecal counts of anaerobic and aerobic 
bacteria and a trend towards a lower ratio of total anaerobes to aerobes. 
 
• Metabolic sequelae were associated with villous atrophy, mucosal inflammation, and 
extent of the disease in the remaining ileum and included decreased levels of albumin, 
calcium, total cholesterol, triglycerides, and vitamin E. Vitamin D and B12 deficiencies 
also occurred. 
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• Lactobacillus rhamnosus GG balanced the bacterial flora by increasing the ratio of 
total lactobacilli to total anaerobes, but did not ameliorate mucosal inflammation. 
 
• No differences appeared between the groups in quality of life. In terms of overall 
satisfaction the patient groups were similar: 90% of conventional ileostomy and 
89% of ileal pouch-anal anastomosis patients were satisfied. 
 
In conclusion, pouchitis is a bacteria-mediated disease in patients immunologically or 
genetically susceptible to ulcerative colitis. Patients with extraintestinal manifestations 
and high-level pANCA should be counseled on their high risk for chronic pouchitis 
after surgery and their potential need for long-term antibiotic treatment. Patients with 
chronic pouchitis will also require long-term follow-up. Patients with conventional 
ilestomies preserve better mucosal morphology and have excellent metabolic outcome 
and good quality of life. In the light of postoperative morbidity and the expected quality 
of life, surgeons should carefully consider both choices of operation and detail all pros 
and cons with patients and their families before surgery. 
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